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Abstract
THE IMPACT OF THE FDA WARNING ON POST-TONSILLECTOMY OPIOID
PRESCRIBING IN PUBLICLY AND PRIVATELY INSURED CHILDREN
By Dianna Julie Soelberg, MSN, CRNA
A dissertation submitted in partial fulfillment of the requirements for the degree of Doctor of
Philosophy at Virginia Commonwealth University
Virginia Commonwealth University, 2020.
Dissertation Chair: Clarence Biddle, PhD., CRNA
Professor, Department of Nurse Anesthesia
Due to reports of significant adverse events, the U.S. FDA placed a Boxed Warning on the opioid
codeine in February 2013 – contraindicating its use in pediatric patients undergoing
tonsillectomy and/or adenoidectomy. Studies conducted in privately insured children showed a
reduction in codeine prescribing and a slight increase in alterative opioid prescribing following
the FDA warning, yet the extent to which the FDA warning impacted prescribing in publicly
insured children is unknown. Using a quasi-experimental interrupted time series design, this
study evaluated codeine and alternative opioid prescribing before and after the FDA warning in
both publicly and privately insured children and compared prescribing between groups. Data on
5603 children undergoing tonsillectomy and/or adenoidectomy at Oregon Health and Science
University from 2010 – 2018 was analyzed via segmented regression analysis. Findings suggest
codeine and alternative opioid prescribing decreased in both groups after the FDA warning and
prescribing was comparable between groups. There was no difference in the mean level (p =
0.664) or pre-post intervention slopes (p = 0.383) of codeine prescribing and no difference in the
mean level (p = 0.103) or pre-post intervention slopes (p = 0.088) of alternative opioid
prescribing between groups. Additional findings of interest included the effect of age, procedure

indication and body habitus on opioid prescribing. Of these, young age appeared to influence
opioid prescribing to the greatest degree. Results of this study indicate codeine and alternative
opioid prescribing decreased after the FDA warning and prescribing did not appear to differ
based on health insurance status, though clinical factors appeared to influenced prescribing.

Keywords: pediatric, tonsillectomy, FDA warning, codeine, opioids, health insurance,
interrupted time series

Chapter 1: Introduction
Study and Chapter Overview
The purpose of this study is to evaluate opioid prescribing in pediatric post-tonsillectomy
and/or adenoidectomy patients before and after the U.S. Food and Drug Administration (FDA)
Boxed Warning on the opioid codeine, formally published in 2013. This study will seek to assess
the impact of the FDA warning on opioid prescribing behaviors in children who underwent
tonsillectomy and/or adenoidectomy and examine if prescribing behaviors were influenced by
health insurance status. Study results will assess the effect of the FDA warning on codeine
prescribing, add additional knowledge on prescribing patterns of alternative/non-codeine
containing opioids and help fill a gap in the literature concerning opioid prescribing behaviors in
publicly and privately insured pediatric post-tonsillectomy and/or adenoidectomy patients.
This chapter provides a brief background on opioid use in pediatric tonsillectomy and/or
adenoidectomy patients and includes a statement of the problem. The study’s purpose and
significance are summarized, followed by brief introductions to the study’s theoretical
framework and methodology. Chapter one concludes with an overview of the remaining
chapters.
Background
Tonsillectomy, with or without adenoidectomy, is one of the most commonly performed
pediatric surgical procedures in the United States (U.S.), with more than 530,000 performed
annually in children less than 15 years of age (Baugh et al., 2011). It represents the second most
common and ninth most cumulatively expensive reason for care in U.S. children’s hospitals
(Keren et al., 2012). Though the procedure and care of a patient undergoing tonsillectomy

1

and/or adenoidectomy is fairly routine, risks do exist – as summarized in Table 1. In particular,
children who suffer from sleep-related breathing disorders have a higher preponderance of
complications (De Luca Canto et al., 2015; Goldman et al., 2013; Mitchell et al., 2019).
Obstructive sleep apnea (OSA) belongs to the continuum of sleep-related breathing disorders and
is a common indication for tonsillectomy and/or adenoidectomy. In fact, of the 530,000 pediatric
tonsillectomies performed annually, 75% are related to OSA (Patino, Sadhasivam, & Mahmoud,
2013; Roland et al., 2011).
Table 1
Risks and Complications of Tonsillectomy and/or Adenoidectomy
Operative Risks

Postoperative Complications

-Trauma to surrounding tissues (teeth, tongue, -Respiratory compromise/apnea*/**
pharynx, soft palate, pharyngeal wall, carotid -Post-tonsillectomy bleeding/hemorrhage***
artery)
-Nausea/vomiting
-Infection
-Pain
-Airway fire/endotracheal tube ignition
-Dehydration
-Difficult intubation*
-Post-obstructive pulmonary edema
-Laryngospasm
-Aspiration pneumonitis
-Laryngeal edema
-Death or anoxic brain injury**
-Respiratory compromise**
-Cardiac arrest
-Death or anoxic brain injury**
Note: *Higher in children with obesity. **Higher in children with OSA. ***Higher in children
without OSA
Information from: (Cote, Lerman, & Anderson. B., 2018; De Luca Canto et al., 2015; Goldman
et al., 2013; Mitchell et al., 2019; Statham & Myer, 2010)
OSA has become a major public health concern. Its incidence and severity in the
pediatric population have increased, in large-part due to the rising rates of childhood obesity
(Marcus et al., 2012; Patino et al., 2013). In the past, a ‘watchful waiting’ approach was taken for
pediatric OSA management. However, when early tonsillectomy was compared with ‘watchful
waiting’ care in randomized controlled trials (RCT), children receiving the surgical intervention
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showed reduction of OSA symptoms, normalization of polysomnography (PSG) sleep-study
indices and improved quality of life (Garetz et al., 2015; Goldstein et al., 2004; Marcus et al.,
2013). A recent Cochrane Database Systematic Review demonstrated high-quality evidence that
early tonsillectomy improved PSG indices and moderate-quality evidence that OSA symptoms,
quality of life and behavior are improved with early tonsillectomy (Venekamp et al., 2015).
Currently, if a child meets criteria for OSA and does not have a contraindication for surgery,
tonsillectomy is recommended as the first-line treatment (Marcus et al., 2012). If left untreated,
the disorder can be associated with significant morbidity, including long-term cardiopulmonary
sequela (Patino et al., 2013).
The tandem rise in early surgical intervention and the growing number of children
suffering from obesity and OSA has created the “perfect storm” where perioperative
complications, particularly respiratory adverse events, are more likely to occur (Coté, Posner, &
Domino, 2014; Marcus et al.,, 2012; Patino et al., 2013). Many of these complications are
related to medications that depress the respiratory drive, such as opioids. Opioids exert their
action on the µ-receptors, which are located throughout the central nervous system and, to a
lesser extent, in the periphery (Pathan & Williams, 2012). Agents that bind to these receptors
cause analgesia – but also other unwanted effects, namely sedation and respiratory depression. In
children with OSA, these effects are markedly increased due to greater opioid-related sensitivity
(Marcus et al., 2012; Patino et al., 2013). Opioids exacerbate pharyngeal collapse, worsen OSA
symptoms and can lead to significant complications, including respiratory adverse events or
death (Coté et al., 2014). Such complications represent major limitations to the use of opioids in
children with OSA.
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Additionally, genetic variations in opioid metabolism further amplifies the risk of opioids
in children undergoing tonsillectomy and/or adenoidectomy. The role of genetic phenotypes and
polymorphisms are known to create noticeable differences in inter-individual drug metabolism. It
is well established that pharmacogenetics was a contributing factor in several codeine-related
adverse events, yet the extent to which pharmacogenetics play a role in the clinical response to
other opioids is not fully elucidated (Parikh, Amolenda, Rutledge, Szabova, & Chidambaran,
2019). Still, it appears as though there is interplay between genetic risk signatures and clinical
risk factors in opioid-related adverse events in children undergoing tonsillectomy and/or
adenoidectomy (Biesiada et al., 2014) – furthering the conditions that generate the “perfect
storm” of complications.
The safety of opioids in children undergoing tonsillectomy and/or adenoidectomy came
under intense scrutiny after several unfortunate events and poor outcomes. For decades,
providers prescribed the opioid codeine for post-tonsillectomy and/or adenoidectomy pain –
however, death and/or serious adverse events were reported after administration of codeine in
some children (Cote et al., 2014). A review of cases reported to the U.S. Food and Drug
Administration's (FDA) Adverse Event Reporting System between 1969 and 2012 identified 10
deaths and 3 overdoses in children who had undergone tonsillectomy and/or adenoidectomy and
were treated with codeine – 8 of which were attributed to OSA related opioid sensitivity and/or
genetic variants leading to rapid metabolism of codeine (Coté et al., 2014; Kuehn, 2013; Tobias,
Green, & Coté, 2016). Subsequently, the FDA contraindicated the use of codeine in all children
undergoing tonsillectomy by placing a Boxed Warning – the FDA’s strongest warning – on the
drug (Kuehn, 2013). Specifically, the 2013 FDA warning advised health care professionals “to
prescribe an alternative analgesic [to codeine] for postoperative pain control in children
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undergoing tonsillectomy and/or adenoidectomy” (U.S. FDA Drug Safety Communications,
2013).
Encouragingly, two recent analyses found a significant reduction in post-tonsillectomy
and/or adenoidectomy codeine prescribing following the FDA warning, with a slight increase in
prescribing of alternative opioids (Chua, Shrime, & Conti, 2017; Van Cleve, 2017). These
authors, and others, have made meaningful contributions to the literature regarding posttonsillectomy codeine and opioid prescribing patterns – however, important gaps in knowledge
remain.
Gaps in Knowledge
One considerable limitation to recent work in the field is the population of interest. Rates
of tonsillectomy and/or adenoidectomy are similar for children insured by Medicaid compared
with those insured by private sources (Boss, Marsteller, & Simon, 2012) – though, to date, all
relevant studies have examined post-tonsillectomy and/or adenoidectomy codeine and opioid
prescribing in privately insured children. Knowledge of post-tonsillectomy prescribing practices
in publicly insured children is unaccounted for. Though it is difficult to tell whether patients with
different types of insurance are treated equally, differences in the medical treatment of publicly
insured children and/or those of low socioeconomic status (SES) versus privately insured
children are suggested (Alexander & Currie, 2017; Boss et al., 2015; Canino et al., 2010;
Sabharwal, Zhao, McClemens, & Kaufmann, 2007). Specifically, differences in opioid
prescribing in publicly versus privately insured children are documented. A recent study showed
pediatric patients with public insurance were more likely to receive an opioid after surgery than
those with private insurance (Donohoe, Zhang, Mensinger, & Litman, 2019). However, other
studies demonstrate that children with private insurance were prescribed more opioids than their
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publicly insured counterparts in non-surgical settings (Groenewald, Rabbitts, Gebert, & Palermo,
2016; Tomaszewski, Arbuckle, Yang, & Linstead, 2018). Though the evidence is mixed, these
findings suggest it is plausible that codeine and/or opioid prescribing differs between publicly
and privately insured children undergoing tonsillectomy and/or adenoidectomy.
The reasons underlying potential prescribing differences in post-tonsillectomy children
are likely subtle and complex. Prescribing decisions may be related to potential implicit or
explicit bias based on certain patient characteristics (Donohoe et al., 2019; Sabin & Greenwald,
2012). These attitudes and beliefs may subtly and unintentionally contribute to disparities in
prescribing practices. Prescribing decisions may also be explained from a clinical perspective.
Providers may prescribe less opioids in publicly insured children due to the higher prevalence of
certain comorbid conditions in this patient population. Children of lower SES (viewed as a proxy
for public insurance) have an increased prevalence of obesity and sleep-related breathing
disorders, such as OSA (Boss et al., 2012; Dudley & Patel, 2016). Given the dangers of the
combination of opioids, obesity and OSA, it is reasonable to hypothesize that providers are more
cautious in prescribing opioids (e.g. prescribe less opioids) to a population of children with a
higher prevalence of these disorders. On the other hand, there is a negative association between
SES and pain prevalence in pediatric post-tonsillectomy children, where those with lower SES
appear to have a higher pain prevalence. This is evidenced by higher rates of emergency room
revisits for pain after tonsillectomy in children with decreasing median incomes (Bhattacharyya
& Shapiro, 2014). To avoid increased health care utilization (emergency room revisits),
providers may prescribe more opioids to those with public insurance.
The combination of recent studies documenting differences in opioid prescribing in
publicly and privately insured children, potential provider biases and clinical explanations for
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prescribing differences give reason to believe codeine and/or opioid prescribing may differ in
public and private pediatric post-tonsillectomy patients.
Problem Statement
Due to its well-documented safety issues, the opioid codeine is contraindicated in all
children undergoing tonsillectomy. It appears that as a result of the FDA warning, codeine
prescribing rates have fallen in privately insured U.S. children, with a slight (non-significant)
increase in alternative opioid prescriptions. Yet, it is unknown to what extent the FDA warning
impacted codeine and alternative opioid prescribing rates in publicly insured children – and if
prescribing rates differ between publicly and privately insured children.
Study Purpose and Research Questions
The purpose of this study is to investigate the relationship between the FDA warning and
codeine/alternative opioid prescribing in publicly and privately insured children who underwent
tonsillectomy and/or adenoidectomy at Oregon Health and Science University (OHSU) between
2010 – 2018. Successful completion of this study will help clarify the impact of the FDA
warning and compare prescribing rates of codeine and alternative opioids between publicly and
privately insured children. This study will seek to answer two questions:
(1) What is the relationship between the FDA warning and codeine/alternative opioid
prescribing in children who underwent tonsillectomy at Oregon Health and Science
University (OHSU) between January 2010-December 2018?
(2) Does the relationship between codeine and/or alternative opioid prescribing in
pediatric post-tonsillectomy children who underwent tonsillectomy at OHSU between
January 2010 and December 2018 vary by health insurance status?
Study Significance
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This study examines the significant clinical dilemma of opioid prescribing in children
undergoing tonsillectomy and/or adenoidectomy. The study will illuminate the impact of the
FDA warning on codeine and alternative opioid prescribing rates in pediatric tonsillectomy
and/or adenoidectomy patients and generate new knowledge by evaluating the problem in the
context of an understudied population. Publicly insured children, who share similar rates of
tonsillectomy and/or adenoidectomy as their privately insured counterparts, have largely been
left out of the body of relevant research. Inclusion of health insurance status as an indicator of
opioid prescribing rates is substantiated by recent work in the field where certain subgroups of
patients, including publicly insured children, were more likely to be prescribed opioids after
surgery (Donohoe et al., 2019). Importantly, this study will contribute a meaningful comparison
of prescribing rates in publicly versus privately insured post-tonsillectomy children – an analysis
that has not been undertaken to date.
Finally, this study advances the body of research in that the implications of codeine
substitution remain unclear. In the ‘no-codeine’ era, prior studies demonstrated a slight, nonsignificant increase in alternative opioid prescribing (Chua, Shrime, & Conti, 2017; Van Cleve,
2017). Because clinical and genetic risk factors may play a role in both codeine and non-codeine
opioid related adverse events (Biesiada et al., 2014), it is important to further the understanding
of codeine-substitution and alternative opioid prescribing rates.
Introduction to Theoretical Framework
The Donabedian model will serve as the theoretical framework for the study.
Donabedian’s landmark article proposed three domains in which the quality of medical care can
be assessed – structure, process and outcome (Donabedian, 1966/2005). The assumption of the
model is that “good structure increases the likelihood of good processes, and good processes
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increase the likelihood of good outcomes” (Donabedian, 1988, p.1145). In this study, the
structure arm of the triad will be the FDA warning; the process arm will be codeine/alternative
opioid prescribing practices before and after the FDA warning and the outcome will be the
number of codeine/alternative opioid prescriptions prescribed.
Emphasizing the need to account for a patient’s environmental and/or personal
characteristics, Donabedian’s model was later modified by Coyle & Battles (1999) to include
antecedent conditions. Antecedent conditions are individuals’ personal and environmental factors
that may influence outcomes of care. Socioeconomic factors, including health insurance status,
have been described as pertinent antecedents to quality health care (Coyle & Battles, 1999) –
providing justification to include health insurance status as antecedent in this study.
The linkage in this study is: The FDA warning (structure) will lead to a change in
prescribing practices (process) and influence the number of codeine and alternative opioid
prescriptions (outcome). Health insurance status (antecedent) may affect the number of codeine
and alternative opioid prescriptions. The theoretical model and linkage will be further explored
in Chapter Two.
Assumptions
The primary assumption in this study is that prescribing providers are aware of the FDA
Boxed Warning on codeine. This assumption can be justified by reviewing the study site’s drug
formulary, which clearly restricts the use of codeine in children < 18 years of age (Lexicomp
Drug Formulary, n.d.). There is also an underlying assumption that the FDA warning for codeine
in tonsillectomy and/or adenoidectomy will remain in effect. Given the well-described dangers
of codeine in children and the various worldwide agencies recommending against the use of
codeine in children (FDA, American Academy of Pediatrics, World Health Organization
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(WHO), United Kingdom Medicines and Healthcare Products Regulatory Agency (UK MHRA)
European Medicines Agency (EMA) and Health Canada (Tobias et al., 2016)), this assumption
can be justified. It is also assumed that no opioid-drug shortages occurred during the study
period.
Delimitations
The time-frame of this study is limited to 2010-2018. The starting year (2010) is
consistent with prior studies (Chua et al., 2017; Van Cleve, 2017) and will provide data for three
consecutive years prior to the 2013 FDA Boxed Warning on codeine. In addition, the data source
(discussed below) is expected to yield complete, electronic data for the entire study interval.
Next, the study sample includes those children who receive care at OHSU and have public or
private insurance. Given federal, state and/or organizational medical assistance programs, very
few children undergo surgery uninsured at OHSU. In 2016, the proportion of uninsured children
in the U.S. was < 5% and in the state of Oregon this percentage is even lower at 3% (Child
Trends, 2017; Oregon Health Authority, 2017). Because inclusion of uninsured children would
lead to substantially unequal study groups, uninsured children will not be included in the
statistical analysis of the health insurance subgroup. Also, children who require posttonsillectomy and/or adenoidectomy inpatient admissions (planned or unplanned) will be
excluded from the study. An inpatient admission allows for greater patient monitoring
capabilities (e.g. pulse oximetry and regular, prescribed bedside monitoring by staff), which may
increase the propensity for a provider to prescribe post-tonsillectomy and/or adenoidectomy
opioids.
A Brief Overview of Methodology
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Research design
This study will employ a quasi-experimental, interrupted time-series design with data
analyzed via segmented regression analysis. Interrupted time-series analyses are the standard for
evaluation of policy actions and segmented regression analyses allow for pre-and postintervention comparisons (Polit & Beck, 2017). Because this study aims to assess the impact of
the FDA warning on pre-and post-FDA warning prescribing practices, this analysis is ideal to
address the research questions.
Summary of data source
Data from this study will be extracted from OHSU’s electronic health record (EHR)
EPIC Hyperspace® platform. The outpatient EPIC Hyperspace® platform was fully integrated
into OHSU in 2008. Thus, the data source is expected to yield full and accurate data.
Definition of Terms
•

Child/children: An individual under the age of 18 years of age (Oregon Laws Legal
Dictionary, 2017).

•

Food and Drug Administration Boxed Warning: Denotes labelling on prescription drugs that
have serious or life-threatening risks; also known as a “Black Box” warning (U.S. Food and
Drug Administration, 2012).

•

Health insurance: An aggregated category that includes: Private health insurance, Medicare,
Medicaid, Children’s Health Insurance Program, Department of Defense, and Department of
Veterans Affairs. These plans provide insurance against medical losses to eligible individuals
and/or families and may directly provide medical care (Center for Medicare and Medicaid
Services, n.d.).
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•

Obstructive Sleep Apnea: “A disorder of breathing during sleep characterized by prolonged
partial upper airway obstruction and/or intermittent complete obstruction that disrupts normal
ventilation during sleep and normal sleep patterns” (American Thoracic Society, 1995, p.
898).

•

Opioid: A group of drugs that bind to opiate receptors in the central and peripheral nervous
systems to elicit analgesia (Pathan & Williams, 2012).

•

Otolaryngologist/otolaryngology: A physician that provides medical and/or surgical therapy
for disease, disorders and/or injuries of the “ears, nose, sinuses, throat, respiratory, and upper
alimentary systems, face, jaws, and the other head and neck systems”; may also be known
known as ear-nose-throat (ENT) physician (American Medical Association, n.d.).

•

Tonsillectomy and/or adenoidectomy: A surgical procedure that completely removes the
tonsil, including its capsule, by dissecting the peritonsillar space between the tonsil capsule
and the muscular wall; may be performed with or without removal of the adenoids; also
known as adenotonsillectomy (Mitchell et al., 2019).

•

Private health insurance: Includes health insurance plans marketed by the private-health
industry; often employer-connected, but may be purchased on the free market. In private
health insurance, premiums are paid to traditional managed care, self-insured health plans
and indemnity plans (Center for Medicare and Medicaid Services: Glossary, n.d.).

•

Public health insurance: A program run by U.S. federal, state, or local governments where
healthcare costs for individuals and/or families are paid for by the government. In the state of
Oregon, the Oregon Health Plan comprises Medicaid and the state children’s health
insurance program (SCHIP), both of which provide low or no-cost health coverage to eligible
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children (Center for Medicaid and Medicare Services, n.d.). Medicare (coverage for
individuals >65 years) is not pertinent to this study.
Chapter Summary
Chapter One provided a background on codeine and opioid use in pediatric tonsillectomy
and/or adenoidectomy patients. It also highlighted opioid prescribing disparities in publicly
versus privately insured children and pointed to a knowledge gap in opioid prescribing patterns
in pediatric tonsillectomy and/or adenoidectomy patients. The Donabedian model with relevant
antecedents was introduced and the study’s methodology was overviewed.
The remaining manuscript includes Chapter Two – Chapter Five. Chapter Two provides a
comprehensive review of the literature and fully explores the theoretical underpinnings for the
study. Chapter Three describes the study’s methodology, including research design, study
variables, study sample and data analysis plan. Chapters Four and Five include results of the
study and discussion of study findings.

13

Chapter 2: Literature Review
Chapter Overview
This chapter reviews literature pertaining to opioid use in pediatric post-tonsillectomy
and/or adenoidectomy patients. The chapter begins by defining pain and postoperative pain,
offers a historical perspective on pediatric surgical pain management, discusses the current state
of post-tonsillectomy and/or adenoidectomy opioid use and identifies factors that contribute to
poor outcomes in pediatric tonsillectomy patients. The research gap is identified, followed by
study aims & hypotheses. A detailed discussion of the Donabedian framework as it relates to the
study is also included.
Background
Definition of pain
Pain has been defined in many ways, though the definition set forth by The Taxonomy
Committee of International Association for the Study of Pain (IASP) offers the most widely
accepted designation: “An unpleasant sensory and emotional experience associated with actual
or potential tissue damage or described in terms of such damage” (International Association for
the Study of Pain (ISAP), 1994/2017). Pain is a multi-dimensional phenomenon that can be
further classified by the pathophysiological mechanism, duration, etiology and anatomic location
of pain (World Health Organization (WHO), 2012; IASP, 1994/2017), as discussed in Table 2.
Table 2
Classification and Characteristics of Pain
Classification of
Pain
Pathophysiologic
Mechanism

Characteristics of Pain
•

Nociceptive: arises from tissue injury, tends to be time-limited and
responsive to opioids. Nociceptive pain can be further differentiated
by the location of activated nociceptors:
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-

Somatic: activation of nociceptors in either surface tissues (skin,
mucosa of mouth, etc.) or in deeper structures (bone, joint,
muscle and connective tissue)
- Visceral: activation of nociceptors located in the internal viscera
(thoracic, abdominal organs, etc.)
• Neuropathic: arises from nerve cell damage or dysfunction in the
peripheral or central nervous systems; tends to be longer lasting and
has a less robust response to opioids.
• Mixed: nociceptive and neuropathic pain that coexists
• Idiopathic: inability to find an underlying cause; may be termed
psychogenic pain
Duration
• Acute: onset of pain is sudden and immediately felt following
injury; the intensity is generally severe but short in duration
• Chronic: continuous or recurrent pain that persists beyond the
expected normal time of healing
• Episodic/Recurrent: pain that occurs intermittently over a long
period of time
Etiology
• Based on the underlying disease and generally classified as malignant
or non-malignant
Anatomic
• Can be classified by body location (e.g. head, back or neck) or the
Location
anatomic function of the affected tissue (e.g. myofascial, rheumatic,
skeletal, neurological and vascular)
Note: Information from: WHO 2012; IASP, 1994/2017
Postoperative pain
Postoperative pain is considered a form of acute pain due to surgical trauma, resulting in
an inflammatory reaction and a cascade of nociceptive activation (Gupta et al., 2010; WHO,
2012). Different surgical procedures involve specific organs and surrounding tissues, creating
various patterns of somatic and/or visceral nociception activation during surgery (IASP, 2017).
The quality, anatomic location and severity of postoperative pain is largely a result of this
nociceptive activation, though it is also influenced by autonomic, endocrine, metabolic and
psychological responses to pain (Brennan, 2011; Gupta et al., 2010). Treatment of acute
postoperative pain relies on therapies that modulate pain transmission; the mainstay of
postoperative pain therapy in many settings is opioids (Garimella & Cellini, 2013). Effective
postoperative pain control is an essential need of any individual undergoing surgery.
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Historical perspective on pediatric postoperative pain
The understanding of postoperative pain in children has advanced considerably over the
last several decades. Long held assumptions that children are more tolerant of pain, are incapable
of pain perception or that provision of pain relief is more harmful than the pain itself, are no
longer scientifically or ethically justifiable (Unruh & McGrath, 2014). In the late 19th and early
20th centuries, clinicians believed pediatric patients tolerated postoperative pain well and seldom
required medication for the relief of pain after surgery (Unruh, 1992). A classic document by
Eland & Anderson (1977) assessed disparities in postoperative pain management between
children and adults and noted that postoperative pain in children was vastly undertreated. Though
the study was not rigorous, it represented a landmark study highlighting the extreme differences
and inadequacy in surgical pain management between children and adults (McGrath, 2011;
Unruh, 1992). Several publications followed, including an early systematic study showing a
dramatic increase in pediatric pain publications in the 1980’s – implying a heightened interest in
the field around this time (Guardiola & Banos, 1980; McGrath, 2011). Since then, the
conceptualization and treatment of pediatric surgical pain has advanced to appreciate the
developmental neurobiology of pain and the importance of adequate analgesia in children
(McGrath, 2011; Schechter, 2014).
Disparities in treatment of pediatric pain led organization such as the Agency for Health
Research and Quality (AHRQ) and the American Pain Society (APS) to provide guidelines for
pediatric pain management (Cote, Lerman, & Anderson, 2018). The AHRQ’s 1993 Clinical
Practice Guideline for Acute Pain Management in Infants, Children and Adolescents: Operative
Procedures (archived and no longer intended to guide medical practice), recommended opioids
such as codeine to be used after minor pediatric surgical procedures. The APS Task Force on
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Pain in Infants, Children and Adolescents (2001) endorsed early treatment of postoperative pain
with non-opioids and opioids, providing a specific recommendation only to avoid the opioid
meperidine. These guidelines and recommendations, crafted with the best available evidence at
the time, served as a platform for safe opioid prescribing practices in children.
Additionally, the World Health Organization (WHO) created initial (1986) and revised
(1996) guidelines on pain relief, based on the well-known “analgesic ladder.” As shown in
Figure 1, the traditional ladder advocates a three-step treatment process, where the first step
centers on non-opioids, the intermediate step relies on weak opioids, such as codeine and
tramadol, and the final step supports use of stronger opioids, such as morphine (Gray, Collins, &
Milani, 2013). Some authors have since devised more recent iterations of the ladder, including a
fourth step of interventional approaches (e.g. nerve blocks) for treatment of persistent pain
(Cuomo, Bimonte, Forte, Botti, & Cascella, 2019; Vargas-Schaffer, 2010). Creation of the WHO
analgesic ladder was significant in that it established the concept of a grading approach to opioid
prescribing. Though the WHO analgesic ladder was not specifically intended for the pediatric
population nor for postoperative pain, these guidelines have been broadly applied to many
patients requiring analgesic therapy – including both pediatric and postoperative patients
(Ballantyne, Kalso, & Stannard, 2016; Cartabuke, Tobias, Taghon, & Rice, 2014; Gray et al.,
2013; Vargas-Schaffer, 2010).
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Figure 1. WHO Analgesic Ladder for Pain. Adapted from: (Vargas-Schaffer, 2010; World
Health Organization, 2012)
Impact of pediatric postoperative pain
As the understanding of pediatric pain improved, so did the ability to appropriately
measure and treat pediatric pain. One of the most notable advances in pediatric pain medicine
was the recognition that untreated or undertreated surgical pain leads to short and long-term
consequences, including detrimental psychological and physiological effects (McGrath & Craig,
1986; Verghese & Hannallah, 2010). Acute postoperative pain causes fear, distress, behavioral
disturbances, disrupted eating and sleeping cycles and harmful neuroendocrine and inflammatory
responses (Cote et al., 2018; Lauder & Emmott, 2014). Additionally, the psychological and
physiological responses to pain may predispose children to develop chronic pain as adults
(Finley, Chorney, & Campbell, 2014). Children experience and process acute postoperative pain,
making provision of adequate postoperative pain control a priority.
Perspective on pediatric post-tonsillectomy pain
Pain following tonsillectomy and/or adenoidectomy is very common, representing a
major cause of post-surgical morbidity (Baugh et al., 2011; Mitchell et al., 2019). Post-
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tonsillectomy and/or adenoidectomy pain is thought to be due to inflammation and irritation of
pharyngeal nerve endings and pharyngeal muscle spasms; it often exhibits a bimodal pattern,
with pain and functional limitations lasting for up to 7-10 days (Lauder & Emmott, 2014;
Rodríguez, Villamor, & Castillo, 2016). Untreated post-tonsillectomy and/or adenoidectomy
pain leads to dehydration, nausea/vomiting, dysphagia, weight loss and unplanned hospital
readmissions (Lauder & Emmott, 2014; Mitchell et al., 2019). Because the majority of
tonsillectomies and/or adenoidectomies are performed on an outpatient basis, pain control is
required following hospital discharge. Though non-opioid analgesic regimens may be optimal,
opioids are still commonly used, with 6 in 10 post-tonsillectomy children filling a prescription
opioid in the perioperative period (Chua et al., 2019).
Codeine in Pediatric Tonsillectomy
Codeine is a weak opioid widely used in the management of mild-moderate pain (He,
Lardieri, & Morgan, 2018). It was historically the primary analgesic agent for post-tonsillectomy
pain, though it has fallen out of favor due to the risk of serious opioid-related adverse events
(Coté et al., 2014). A review of basic opioid pharmacology is offered below, followed by
specific information pertaining to codeine analgesia.
Basic opioid pharmacology
Opioids produce their analgesic action by activating opioid receptors, which are located
in the central nervous system (brain and spinal cord) and, to a lesser extent, in peripheral tissues
(Pathan & Williams, 2012; Trivedi, Shaikh, & Gwinnut, 2008). Three classic types of opioid
receptors have been identified: mu, kappa and delta opioid receptors (Hemmings & Egan, 2019).
Opioids have a higher affinity for mu-receptors than the kappa or delta receptor subtypes, though
all receptor subtypes have important physiological effects (Andrzejowski & Carroll, 2016).
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When opioid receptors are activated, a spectrum of physiological effects occur, as shown in
Table 3. Notably, respiratory depression and sedation are characteristic of mu-opioid receptor
activation.
Table 3
Physiological Effects of Opioid Receptors
Mu

Kappa

Delta

Yes

Yes

Yes

Yes, marked

No

Possibly, minimal

Yes, marked

No

Possibly, minimal

Gastrointestinal
effects
Genitourinary effects

Yes

No

Yes

Yes

No

Yes

Euphoria

Yes

No

Possibly, minimal

Dysphoria
(restlessness/agitation)
Abuse potential

No

Yes

No

Yes

No

Yes

Spinal & supraspinal
analgesia
Respiratory
depression
Sedation

Note: Adapted from: (Flood, Rathmell, & Shafer, 2015; Hemmings & Egan, 2019; Trescot,
Datta, Lee, & Hansen, 2008)
Both endogenous and exogenous substances interact with opioid receptors to elicit a
physiological response. Opioid receptors are normally stimulated by endogenous peptides
(endorphins, enkephalins, and dynorphins) that are produced in response to noxious stimulation
(Trescot, Datta, Lee, & Hansen, 2008). Exogenous substances are naturally occurring, semisynthetic or synthetic opioid compounds that bind to any subpopulation of the opioid receptor,
mimicking the action of endogenous substances (Flood et al., 2015). Activation of the mu-opioid
receptor by an exogenous agonist is thought to be the major mechanism in opioid-induced
analgesia (Pathan & Williams, 2012).
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Morphine, a mu-receptor opioid agonist, is considered the prototypical opioid analgesic
to which all others are compared (Hemmings & Egan, 2019; Pathan & Williams, 2012). Many
commonly used semisynthetic or synthetic opioids are created by chemical modification or
synthesis from the morphine molecule (Flood et al., 2015; Pathan & Williams, 2012). Each
modification of the morphine molecule yields a derivative with differing, but “morphine-like”,
properties (Flood et al., 2015). One particular property that differs among opioid derivatives is
analgesic potency. As shown in Table 4, opioids were traditionally classified based upon this
property (Trivedi et al., 2008). The designation of opioids based on potency is the basis for the
WHO’s analgesic ladder and grading approach to opioid prescribing.
Table 4
Opioid Classification Based on Potency
Strong

Intermediate

Weak

Morphine
Meperidine
Fentanyl
Alfentanil
Remifentanil
Sufentanil

Buprenorphine
Butorphanol
Nalbuphine

Codeine
Tramadol

Note: Adapted from: Trivedi et al., 2008
Codeine overview
Codeine received U.S. FDA approval in 1950 and has been a commonly used analgesic
for postoperative pain in adults and children for more than 50 years (Andrzejowski & Carroll,
2016). In 2011, codeine-containing prescriptions were prescribed to more than 18 million
children under 11 years of age – making it the most prescribed opioid at that time (Cartabuke et
al., 2014; Chidambaran, Sadhasivam, & Mahmoud, 2017). Codeine is a naturally occurring
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alkaloid compound, acting as an agonist at the mu-opioid receptor (Pathan & Williams, 2012).
When compared to morphine, it possesses a 200-fold weaker affinity for the mu-opioid receptor
– hence its status as a “weak” opioid (Chidambaran et al., 2017; Hansen, Shah, & Benzon, 2016).
Oral codeine is rapidly absorbed, reaching plasma concentration levels within 1 hour of
administration in adults and slightly longer in children (Andrzejowski & Carroll, 2016). The
half-life of codeine is approximately 3-3.5 hours and therapeutic effects of codeine are similar in
adults and children, generally lasting for 4-6 hours (Andrzejowski & Carroll, 2016; Cote et al.,
2018). Common side effects of codeine are listed in Table 5. Codeine is eliminated by either
direct renal excretion or following metabolism via the cytochrome (CYP) 450 system in the liver
(Chidambaran et al., 2017).
Table 5
Common Side Effects of Codeine
Airway and
Breathing
Effects

Cardiovascular
Effects

Central Nervous
System Effects

Gastrointestinal
Effects

Other
Effects

-Shortness of
breath
-Respiratory
depression
-Decreased
cough

-Flushing

-Drowsiness
-Sedation
-Dizziness
-Lightheadedness

-Nausea
-Vomiting
-Constipation

-Sweating

Note: Adapted from: (FDA, 2010; Andrzejowski & Carroll, 2016)
Codeine is a pro-drug, requiring conversion of the drug into its active form to produce
analgesia (Chidambaran et al., 2017; Fortenberry, Crowder, & So, 2018; He, Lardieri, &
Morgan, 2018). As shown in Figure 2, the drug has three major metabolic pathways: 70-80% of
codeine is metabolized by the enzyme UDP-glucuronosyltransferase-2B7 (UGT2B7) into
codeine-6-glucuronide (active drug); 5-10% is metabolized by the cytochrome P450 (CYP) 3A4
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enzyme into norcodeine (inactive); 10% of the drug undergoes O-demethylation via CYP 2D6
enzyme to morphine (active) (Biesiada et al., 2014; Chidambaran et al., 2017; Fortenberry et al.,
2018). The greatest degree of analgesia is produced from the active metabolite morphine
(Chidambaran et al., 2017).

Figure 2. Codeine Metabolism
Note: Adapted from Fortenberry et al., 2008
Background on codeine use in pediatric tonsillectomy
For decades, codeine analgesia was the primary agent for outpatient analgesia after
tonsillectomy and/or adenoidectomy in children (Constant et al., 2014; Lauder & Emmott, 2014;
Tobias et al., 2016). Otolaryngologists prescribe codeine at greater rates than dentists,
pediatricians and general/family practice physicians (Chidambaran et al., 2017). Codeine
analgesia was favored by otolaryngologists for post-tonsillectomy and/or adenoidectomy pain for
numerous reasons, as outlined in Table 6.
Table 6
Reasons for Codeine Use in Post-tonsillectomy Pediatric Patients
Favorable characteristics of
codeine

Rationale for use in post-tonsillectomy
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Can be administered orally via a
liquid or tablet
Is a step-2 analgesic in the WHO
analgesic ladder

Oral opioids can be initiated and continued after
discharge from the hospital
Was thought to be effective for mild-moderate posttonsillectomy pain

Is considered a ‘weak’ opioid

Is weaker than morphine and was thought to have a good
safety profile
Causes less postoperative nausea
Nausea/vomiting is a common problem after
and vomiting than morphine
tonsillectomy and/or adenoidectomy, with an incidence
ranging from 15-80%
Greater ease of prescribing
Codeine co-formulated with acetaminophen is the only
opioid analgesic classified as a Schedule III controlled
substance, allowing for verbal and facsimile prescribing
to pharmacies as well as refills with the original
prescription; also, the drug did not require triplicate
prescription forms in many states
Is relatively inexpensive
Represented a cost-effective therapy option for posttonsillectomy and/or adenoidectomy pain
Note: Information from: (Chidambaran et al., 2017; Constant et al., 2014; Cote et al., 2018;
Garimella & Cellini, 2013; Hansen et al., 2016; Lauder & Emmott, 2014; Semple et al., 1999;
WHO, 2012)
Current state of codeine use in pediatric tonsillectomy
The favorable characteristics of codeine have since been outweighed by its association
with significant adverse events, including deaths and near deaths. In 2009, a fatality occurred in a
healthy 2-year-old boy who was given codeine after adenotonsillectomy (Ciszkowski & Madadi,
2009). This was followed in 2012 by three additional deaths and two cases of respiratory
insufficiency in children who underwent adenotonsillectomy (Kelly et al., 2012). In 2013, three
additional codeine-related deaths occurred in children aged 4-10 years who were prescribed the
recommended weight-based dose of codeine (Friedrichsdorf, Nugent, & Strobl, 2013).
These reports of deaths and near deaths in children receiving standard doses of oral
codeine prompted the FDA and international regulatory agencies to review the safety of the drug
in children undergoing tonsillectomy and/or adenoidectomy. Subsequently, the FDA, WHO,
European Medicines Agency (EMA), the UK Medicines and Healthcare Products Regulatory
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Agency (MHRA) and Health Canada made formal recommendations against the use of codeine
containing products in all children undergoing tonsillectomy and/or adenoidectomy. Figure 3
depicts the progression of the ‘codeine-ban’ in children: It was first recommended that codeine
be avoided in any child undergoing tonsillectomy and/or adenoidectomy; this has been followed
by more recent guidelines to avoid codeine-containing cough elixirs in all children <18 years of
age.

Figure 3. Depiction of the Codeine Ban. Information from (European Medicines Agency, 2013,
2015; Health Canada, 2016; U.S. Food and Drug Administration, 2013, 2018; UK Medicines and
Healthcare Products Regulatory Agency, 2013, 2015; World Health Organization Expert
Committee, 2011)
Contributing Factors in Post-tonsillectomy Deaths and/or Adverse events
Though codeine plays a major role in post-tonsillectomy deaths and/or adverse events, it
is not solely to blame. Rather, several factors have been implicated in the “perfect storm” of
post-tonsillectomy complications including comorbid conditions, opioid sensitivity, genetic
polymorphisms in opioid metabolism, and other factors (Coté et al., 2014; Cote et al., 2018).
Comorbid conditions
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Obesity
Defined by the Center for Disease Control (CDC) as a body mass index >95th percentile
for age and gender, obese children are more likely to suffer from a number of comorbid
conditions including cardiovascular disease (hypertension, dyslipidemia), respiratory disorders
(OSA, asthma), endocrinopathies (diabetes, metabolic syndrome), renal and liver dysfunction
(Cote et al., 2018). Obesity presents challenges during the perioperative period and increases the
risk of poor outcomes. In a large study of post-tonsillectomy morbidity and mortality, obesity
was the second most common predisposing factor for perioperative adverse events (Goldman et
al., 2013). Obese children have a higher incidence of adverse respiratory events during and after
surgery when compared with normal-weight children (Mortensen, Lenz, Abildstrøm, &
Lauritsen, 2011). Increased tissue mass, alterations in respiratory mechanics, reduction in lung
capacities and airway narrowing are thought to contribute to the heightened risk profile of obese
children (Mortensen et al., 2011; Patino et al., 2013). In 2009, researchers found that obese
children represented 21% of all children undergoing tonsillectomy (Nafiu et al., 2009). A decade
later, it is likely this percentage has increased.
Obstructive sleep apnea
Over 75% of children presenting for tonsillectomy suffer from OSA (Patino et al., 2013).
OSA is a sleep-related breathing disorder that is characterized by intermittent cessation of air
exchange that disrupts normal ventilation and sleep patterns (American Thoracic Society, 1996).
It is further defined as central (lack of respiratory effort due to a central defect), obstructive
(upper airway obstruction) or mixed (central and obstructive problems) and is diagnosed via
clinical assessment or polysomnography (PSG) sleep study (Cote et al., 2018; Marcus et al.,
2012). Symptoms of OSA include obstructed breathing, snoring, paradoxical chest wall motion,
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increased respiratory effort, apneas/hypopneas, hypercarbia and oxygen desaturation. The
spectrum of OSA ranges from mild to severe, based on the total number of obstructive episodes
and oxygen desaturations during sleep (Cote et al., 2018; Patino et al., 2013). OSA occurs in
about 2-5% of all children and can afflict a child of any age, but is more common in children
aged 3-7 years (Marcus et al., 2012). It affects boys and girls equally, though the disorder has a
greater prevalence in African American and Hispanic children when compared with Caucasian
children (Dudley & Patel, 2016).
The incidence of pediatric OSA and sleep-disordered breathing has risen dramatically –
in large part due to the rise in childhood obesity (Marcus et al., 2012; Patino et al., 2013).
Though pediatric OSA is a multifactorial disease, obesity is a predisposing factor – leading to a
higher prevalence of the disorder and exacerbating the symptoms of OSA (Cote et al., 2018;
Patino et al., 2013). OSA is reported in 14-59% of obese children, compared to 1-2% in nonobese children, and the degree of OSA parallels the degree of obesity (Cote et al., 2018; Verhulst
et al., 2008). In general, children with obesity suffer from the obstructive-type of OSA, where
increased resistance to air flow and airway obstruction are characteristic of the disorder (Patino
et al., 2013).
Tonsillectomy and adenoidectomy is recommended as the initial treatment in children
with OSA, yet the presence of OSA significantly increases the odds for post-tonsillectomy
complications (Cote et al., 2018). A recent meta-analysis demonstrated differences in the
distribution of post-tonsillectomy complications between children with OSA and those without.
Canto et al. (2015) showed children with OSA have a 5-fold increase in the odds for
perioperative respiratory events when compared to children without OSA. Also, several recent
studies reported unexpected deaths and/or near deaths following tonsillectomy and/or
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adenoidectomy related to suspected or confirmed sleep apnea (Coté et al., 2014; Goldman et al.,
2013). The risk of complications related to OSA appears to be due to a confluence of factors
including impaired hypoxic and hypercarbic ventilatory responses, pharyngeal collapse leading
to airway obstruction, opioid sensitivity with exaggerated respiratory depression, and improper
post-operative monitoring (Collins, 2015; Coté et al., 2014; Cote et al., 2018; Goldman et al.,
2013; Mortensen et al., 2011). Notably, though tonsillectomy and/or adenoidectomy is
considered to be an effective treatment for OSA, the symptoms of OSA may become worse
during the immediate post-operative period (Marcus, et al., 2012) – making it a particularly
vulnerable time.
Opioid sensitivity
Due to the intermittent airway obstruction during sleep that is characteristic of OSA,
children with OSA experience recurrent episodes of nocturnal desaturation and hypoxemia (Cote
et al., 2018). Although the molecular basis for the effect of nocturnal hypoxemia on opioid
receptors is not fully understood, research shows that exposure to nocturnal hypoxemia increases
the density of mu-opioid receptors in respiratory-areas of the central nervous system (Johnson &
Netzer, 2015; Lam, Kunder, Wong, Doufas, & Chung, 2016). This effect is observed in both
animals and humans. In experimental rat pup models, exposure to recurrent hypoxia was linked
to upregulated opioid receptors in the brainstem and greater respiratory sensitivity to opioids
(Moss, Brown, & Laferrière, 2006; Wu, Li, Wu, & Chen, 2015). Clinical studies are consistent
with this finding where children with OSA had a higher incidence of apnea at uniform doses of
opioids and required less opioid analgesia following tonsillectomy (Brown, 2009; Waters,
McBrien, Stewart, Hinder, & Wharton, 2002). The altered mu-opioid receptor response to
opioids results in patients with OSA being analgesic at lower blood levels of opioids (Coté,
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2015). Thus, children with OSA require less opioids than their non-OSA counterparts and a
normal dose of opioid is a relative overdose in a child with OSA (Coté et al., 2014).
Genetic polymorphisms affecting opioid metabolism
Genetic polymorphisms that contribute to individual variability in opioid-metabolism
have been implicated in post-tonsillectomy deaths and near deaths (Andrzejowski & Carroll,
2016; Chidambaran, et al., 2017) . Codeine is particularly affected by genetic polymorphisms
and will be discussed following a general overview of drug metabolism.
General overview of drug metabolism
In general, drug metabolism occurs in the liver and is classified as either a Phase I or
Phase II reaction, where the former is an oxidative, reduction or hydrolysis reaction and the latter
are conjugation reactions (Hemmings & Egan, 2019). Often drugs undergo both phases of
metabolism, first undergoing a Phase I reaction to increase the drug’s polarity followed by a
Phase II reaction to conjugate the drug to a water-soluble compound for subsequent excretion
(Flood et al., 2015). Both Phase I and II metabolic pathways involve enzyme systems. Phase I
reactions rely primarily on the CYP 450 system, which is a large family of membrane-bound
hemeproteins that catalyze the metabolism of endogenous or exogenous compounds (Flood et al.,
2015; Hemmings & Egan, 2019). Numerous CYP proteins have been identified and different
CYP 450 pathways are classified by similar gene sequences; they are first assigned a family
number (e.g. CYP2), then a sub-family letter (e.g. CYP2D) and are differentiated by a number
for the specific enzyme (e.g. CYP2D6) (McDonnell & Dang, 2013). The CYP 450 system plays
a key role in the metabolism many drugs, including opioids.
Codeine
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As discussed above and illustrated in Figure 2, codeine follows three major metabolic
pathways to produce active and inactive forms of the drug. The primary analgesic effect of
codeine is its conversion to morphine via the CYP450 system, specifically the CYP2D6 enzyme
(Chidambaran et al., 2017; Fortenberry et al., 2018; Kirchheiner et al., 2007). The potential
dangers of codeine lie primarily in genetic polymorphisms of this enzyme.
Variability in the clinical response to codeine prompted inquiries into the role of genetic
polymorphisms of the CYP2D6 enzyme on codeine-related adverse events. The CYP2D6
enzyme is encoded by a gene located on chromosome 22 at 22q.13.1; more than 100
polymorphisms of CYP2D6 have been identified, leading to a broad range of phenotypic activity
of the enzyme (Andrzejowski & Carroll, 2016; Chidambaran et al., 2017). Depending on which
maternal and paternal alleles an individual inherits, the metabolism profile of codeine varies
from poor to ultra-rapid metabolism, drastically affecting the clinical response to codeine
(Andrzejowski & Carroll, 2016; Chidambaran et al., 2017; Kirchheiner et al., 2007). The major
polymorphisms of CYP2D6, as shown in Table 7, alter the clinical response to codeine by
significantly reducing or augmenting the conversion of codeine to morphine (Crews et al., 2012;
Fortenberry et al., 2018). This corresponds with either reduction in its intended therapeutic
effect or heightened therapeutic effect with the potential for significant morphine toxicity (Crews
et al., 2012; Lam et al., 2014).
Table 7
Major Polymorphisms of CYP2D6 Enzyme
Phenotype
Poor metabolizer

Enzyme
Activity Score
0

Genotype

Incidence

Two non5-10%
functioning alleles

30

Codeine
Analgesic
Effect
Very little
analgesic effect

Intermediate
metabolizer

0.5

One non2-11%
Reduced
functioning allele
analgesic effect
& one decreasedfunctioning allele
Normal
1-2
Two normally
77-92%
Expected
metabolizer
functioning alleles
analgesic effect
Ultra-rapid
2
Gene duplication
1-2%
‘Overdose’
metabolizer
of normally
analgesic effect
functioning alleles
Information from: (Andrzejowski & Carroll, 2016; Chidambaran et al., 2017; Coté, 2015; Crews
et al., 2012; Dean, 2012)
Genetic testing is available for common CYP2D6 variants (~30 alleles) (Dean, 2012).
Both maternal and paternal variant alleles, known as diplotypes, are reported; then an activity
score is assigned to each allele in the diplotype, as shown in Table 7 (Andrzejowski & Carroll,
2016; Chidambaran et al., 2017). Though available, the practicality, payer coverage and
affordability limit routine preoperative genetic phenotyping (Chidambaran et al., 2017).
Genetic testing has been undertaken in post-mortem analysis of codeine-related fatalities.
In 2009, a 2-year-old toddler with OSA suffered fatal respiratory arrest after tonsillectomy and
adenoidectomy; post-mortem analysis revealed a serum morphine concentration of 32 nanograms
per milliliter (ng/mL) (therapeutic range = 4.5 + 2.1 ng/mL) and duplicate CYP2D6 alleles,
indicating ultra-rapid metabolizer status (Ciszkowski & Madadi, 2009). Similar cases have since
been reported: a 4-year-old boy and a 3-year-old girl with OSA and a 5-year old boy without
OSA – post-mortem morphine concentrations in these children were 17.6, 17 and 30ng/mL,
respectively; all were found or predicted to have duplicate or mutant CYP2D6 alleles (Kelly et
al., 2012). In all cases, the prescribed dose of codeine was appropriate, based on the child’s
weight, and the reported dose administered by the caregivers were within the boundaries of the
prescribed dose.
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Limited prospective work has evaluated the role of genetic variations on opioid
metabolism. In 2007, Kirchheiner and colleagues administered codeine to 16 individuals with
known CYP2D6 gene alterations and found that those with CYP2D6 genotypes predicting ultrametabolism (gene duplication) had a 50% higher plasma morphine concentration than those
without gene duplication (Kirchheiner et al., 2007). Biesiada and colleagues (2014) conducted a
prospective study (n=273) to evaluate genetic variants associated with respiratory depression in
children undergoing tonsillectomy and adenoidectomy with morphine analgesia. The researchers
found inter-individual differences in morphine-related post-operative respiratory depression,
where certain genetic alleles helped discriminate between low and high risk for post-operative
respiratory depression (Biesiada et al., 2014).
Presently, there are no diseases or conditions known to be linked to CYP2D6 variants –
however there is increasing evidence of ethnic variations in cytochromes responsible for drug
metabolism (Andrzejowski & Carroll, 2016; Cote et al., 2018). Populations that exhibit ultrarapid metabolism include Ethiopians (30%), North Africans/Arabs (16-30%),
Italians/Greeks/Spaniards/Portuguese (10%) and Caucasians (1-10%) and poor metabolizer
populations include Chinese (30%) and Caucasians (5-10%) (Andrzejowski & Carroll, 2016;
Chidambaran et al., 2017). However, CYP2D6 cannot be predicted based on ethnicity alone; the
only definitive means of knowing genetic signatures is via enzyme mapping (Chidambaran et al.,
2017).
Other opioids
The role of genetic polymorphisms affecting codeine metabolism is well documented,
however the extent to which pharmacogenetics influences the metabolism of other opioids is
evolving. Other mild-moderate opioids, such as tramadol, oxycodone and hydrocodone were
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thought to be a safer alternative to codeine – though these drugs may exhibit similar interindividual genetic variations in metabolism because they are, in part, metabolized by CYP2D6
(Andrzejowski & Carroll, 2016; Chidambaran et al., 2017; Crews et al., 2012). Tramadol and, to
a lesser extent, hydrocodone and oxycodone may not be good alternatives to codeine because
their metabolism is affected by CYP2D6 activity (Crews et al., 2012; Dean, 2012).
Tramadol is metabolized by two pathways in the liver: moderate metabolism via
CYP3A4 and extensive metabolism via CYP2D6. CYP3A4 metabolizes tramadol into an
inactive compound, N-desmethytramadol, whereas CYP2D6 metabolizes tramadol into an active
compound, O-desmethyltramadol (Fortenberry et al., 2018). The active metabolite has a 200-fold
greater affinity for the mu-opioid receptor than the parent drug and is predominantly responsible
for the drug’s analgesic effect (Crews et al., 2012). A prospective, double blind RCT found
tramadol was safer than codeine/acetaminophen in pediatric tonsillectomy and/or adenoidectomy
patients, with tramadol causing less respiratory depression and sedation (Friedrichsdorf et al.,
2015). However, there is evidence for decreased efficacy of tramadol in poor metabolizers and
case reports of respiratory distress and near fatalities in ultra-rapid metabolizers – indicating
genetic polymorphisms play a role in the clinical response to tramadol (Crews et al., 2012;
Elkalioubie et al., 2011; Poulsen, Arendt-Nielsen, Brøsen, & Sindrup, 1996; Stamer et al., 2007).
One recent report highlights a case of severe tramadol-related respiratory depression in a child
with OSA undergoing tonsillectomy and adenoidectomy (Orliaguet et al., 2015). As a result, the
FDA also took a stance on tramadol administration in pediatric tonsillectomy and/or
adenoidectomy patients. In 2017, a Boxed Warning and labeling change to avoid tramadol in
pediatric tonsillectomy and/or adenoidectomy patients < 18 years of age was announced (U.S.
Food and Drug Administration, 2017).
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Oxycodone is also metabolized by CYP34A and CYP2D6, though the metabolic profile
differs from tramadol in that CYP34A is the predominant metabolic pathway and CYP2D6 plays
a relatively minor role (Chidambaran et al., 2017). The byproducts of CYP34A and CYP2D6
metabolism are noroxycodone, a metabolite with weak analgesic properties, and oxymorphone,
which possesses 14 times more potency than the parent drug (Chidambaran et al., 2017; Lauder
& Emmott, 2014). Current understanding of oxycodone’s pharmacogenetics is limited,
particularly in pediatrics. In a randomized crossover double-blind study of 10 healthy adult
volunteers, oxycodone pharmacodynamics differed depending on CYP2D6 polymorphisms,
where ultra-rapid metabolizers experienced increased effects (Samer et al., 2010). Stamer and
colleagues (2013) later demonstrated the number of functionally active CYP2D6 alleles had an
impact on oxycodone metabolism in adult postoperative patients, causing variation in clinical
response to oxycodone. At least one case has been reported where a non-fatal toxicity occurred
in an adult patient with impaired CYP2D6 metabolism (Foster, Mobley, & Wang, 2007). There
is no FDA contraindication on oxycodone, though more data is required to understand the impact
of pharmacogenetics on oxycodone metabolism in children.
Hydrocodone is partially metabolized via CYP3A4 and CYP2D6 into hydromorphone
and norhydrocodone, respectively (Chidambaran et al., 2017). Hydromorphone is the active

compound and has a 10-to 33-fold greater affinity for mu-opioid receptors as compared with
the parent drug (Crews et al., 2012). Again, the pharmacogenetic data for hydrocodone is
limited and no pediatric data exists. There is some evidence that hydromorphone is generated
at substantially different rates in adults depending on CYP2D6 genotype and that poor
metabolizers may have a limited analgesic effect to hydrocodone (Otton et al., 1993; Stauble
et al., 2014) – yet there is insufficient data to understand whether ultra-rapid metabolizers
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have an increased risk of hydrocodone related toxicity (Crews et al., 2012). No hydrocodone
fatalities related to CYP2D have been reported and no FDA warnings have been placed on
the drug in the context of pediatric tonsillectomy and/or adenoidectomy.
The differing associations of CYP2D6-related variation in metabolism of codeine and
tramadol as compared with oxycodone and hydrocodone may be related to the relative roles of
the parent drug and circulating metabolites (Crews et al., 2012; Dean, 2012). Based on
pharmacogenetics data, oxycodone and hydrocodone may be less prone to unintended sedation
when compared with codeine and tramadol. However, it critical to consider clinical risk factors,
such as obesity and OSA, along with genetic risk signatures – as both play a role in opioidinduced adverse events.
Other factors
In addition to comorbid conditions and genetic risk factors, other factors implicated in
post-tonsillectomy deaths and/or adverse events include inadequate preoperative assessment for
OSA, performing outpatient surgery in high-risk populations and lack of appropriate postoperative monitoring in the hospital or home setting (Coté, 2015; Coté et al., 2014; Patino et al.,
2013). These, in addition to opioid therapy, are expressed as preventable factors in posttonsillectomy deaths and/or adverse events (Coté et al., 2014).
Opioid Prescribing in the Post-codeine Era
There is strong evidence against the use of codeine and evolving evidence that
substitution of other opioids may be unsafe in pediatric tonsillectomy and/or adenoidectomy
patients. Since the FDA Boxed Warning on codeine, two large-scale and one single-center
observational study analyzed the impact of the FDA warning on codeine and opioid prescribing
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in pediatric tonsillectomy and/or adenoidectomy patients. These studies are described below and
summarized in Table 8.
Table 8
Summary of Relevant Literature
Study
Chua et
al. (2017)

Van
Cleve
(2017)

Goldman
et al.
(2018)

Population &
Sampling Frame
Post-tonsillectomy
and/or
adenoidectomy
children < 18 years
(n=362,992);
Truven MarketScan
Commercial Claims
and Encounters
database, years
2010 – 2015.
Post-tonsillectomy
and/or
adenoidectomy
children < 18 years
of age (n=230,744);
Truven MarketScan
Commercial Claims
and Encounters
database, years
2010 – 2015.
Post-tonsillectomy
and adenoidectomy
children aged 2-12
years; Medical
record data, years
2010 – 2015.

Outcome
Measures
> 1 prescription
fill for codeine or
other opioids
within 7 days of
surgery.

Results

Limitations

Significant
reduction in
codeine dispensed
from 2010 to 2015
in children with
and without OSA.
Non-significant
increase in other
opioids dispensed.

Opioids
dispensed from 2
weeks prior until
2 days following
tonsillectomy &
14-day
postoperative
rates of
emergency
department (ED)
visits.
Post-operative
opioids
prescribed by
academic and
non-academic
otolaryngologists.

Significant
reduction codeine
dispensed from
2010 to 2015;
Non-significant
increase in other
opioids dispensed;
No change in 14day ED visit rates.

Privately insured
children only.
Claims data
captures opioids
dispensed, not
opioids prescribed.
Unable to discern
type of providers
who prescribed
opioids.
Demographics not
presented. Privately
insured children
only. Claims data
captures opioids
dispensed, not
opioids prescribed.
Unable to discern
type of providers
who prescribed
opioids.
Single center study.
Health insurance
status not reported.
Post-operative
prescribing time
parameters unclear.
Did not define
“other narcotics”.

Significant
reduction in
codeine prescribed
by academic and
non-academic
otolaryngologists;
No change in postoperative ED visit
rates.

Using the Truven MarketScan Commercial Claims and Encounters database, Chua and
colleagues (2017) identified 362,992 privately insured children who underwent tonsillectomy
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and/or adenoidectomy between 2010 – 2015. The researchers measured the occurrence of >1
codeine or alternative opioid (hydrocodone, oxycodone and other opioids) prescription fill within
7 days of surgery and made pre-and post-FDA warning comparisons. The monthly rate of change
in codeine prescribing following the FDA warning was significant and negative (-13.3; 95% CI =
[-14.5 to -12.1]), where codeine prescribing fell from 30.1% in 2010 to 5.1% in 2015 (Chua et
al., 2017). Changes in alternative opioid prescribing were found to be slight and non-significant,
with 31.7% fills in 2010 and 46.1% in 2015.
Van Cleve (2017) also studied the impact of the FDA warning on opioid prescribing in
pediatric post-tonsillectomy patients. Using the same commercial insurance database as Chua et
al. (2017), data on 230,477 pediatric tonsillectomies between 2010 – 2015 were analyzed.
Acetaminophen-codeine, acetaminophen-hydrocodone, oxycodone or ‘other’ prescription fills
from two weeks prior until two days post-surgery were identified and classified as pre-or postFDA warning. Van Cleve (2017) found a significant reduction in post-FDA warning codeine
prescribing, where the relative risk (RR) of receiving a codeine-containing prescription in the
post-FDA warning period was RR=0.31 (95% CI, = [0.31-0.32]). The RR of receiving a
hydrocodone or oxycodone-containing prescription in the post-FDA warning period was slightly
increased, though not significant.
The Goldman et al. (2018) study added additional knowledge by comparing prescribing
practices in academic and non-academic otolaryngologists. Though a significance level was not
reported, the researchers noted that academic otolaryngologists’ prescribing reached zero faster
than the non-academic otolaryngologist group (Goldman, Ziegler, & Burckardt, 2018). The
researchers also found an overall 5% reduction in postoperative opioid use by both academic and
non-academic otolaryngologists (p < .001). However, aside from noting hydrocodone was the
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most frequently prescribed post-FDA warning opioid (accounting for 91% of such prescriptions),
the study did not report which other opioids were substituted for codeine.
Goldman et al. (2018) did not report granular information on “other narcotics”, but both
Chua et al. (2017) and Van Cleve (2017) found an increase in alternative opioid prescribing after
the FDA warning on codeine. Though these results were non-significant, this data still provides
useful trends on which non-codeine containing opioids are substituted for codeine. As shown in
Table 9, Chua and colleagues (2017) present detailed information on which alternative opioids
have seen the greatest substitution since the FDA warning on codeine. Van Cleve (2017) and
Goldman et al. (2018) also found hydrocodone to be the opioid most frequently prescribed in the
post-FDA warning era.
Table 9
Substitution Trends of Alternative Opioids
2010

2015

CODEINE

46.8 %

9.1 %

HYDROCODONE

48.4 %

72.7 %

OXYCODONE

3.8 %

17.4 %

OTHER OPIOID

0.1 %

0.8 %

Research Gaps in Post-tonsillectomy Opioid Prescribing
The literature to date contributed beneficial knowledge on the impact of the FDA
warning on codeine and opioid prescribing in pediatric tonsillectomy and/or adenoidectomy
patients, though important gaps remain. As introduced above, both Chua et al. (2017) and Van
Cleve (2017) analyzed the same commercial insurance database – Truven MarketScan
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Commercial Claims and Encounters database. This database reports de-identified, patient-level
data for over 50 million employee-sponsored insured Americans annually (Truven Healthcare
Analytics, 2017). Utilizing this dataset is good for generalizability to other similarly insured U.S.
children, though it leaves a segment of the childhood population underrepresented: publicly
insured children. Van Cleve (2017) lists this as a “major limitation” to his work (p. 1052) and
Chua et al. (2017) note the generalizability of the results to other commercially insured children
and to publicly insured children is unclear. Goldman et al. (2018) did not specify insurer status in
their work, rather focused on academic versus non-academic prescribing providers. Collectively,
no study has evaluated the impact of the FDA warning on publicly insured post-tonsillectomy
children, nor has any study compared opioid prescribing between publicly and privately insured
post-tonsillectomy children. Children enrolled in Medicaid constitute an important population to
study, given an estimated 40% of US children have health insurance coverage by Medicaid
(Kaiser Family Foundation, 2018). Additionally, tonsillectomy rates in publicly and privately
insured children are similar with rates of 81.5 and 80.6 per 10,000 U.S. children, respectively
(Boss et al., 2012) – making post-tonsillectomy opioid prescribing relevant and important in both
subsets of children. The extent to which publicly and privately insured children may be treated
differently is a source of controversy (Alexander & Currie, 2017) and will be examined below.
Further, both the Chua et al. (2017) and Van Cleve (2017) studies analyzed prescription
opioids filled (e.g. dispensed by the pharmacy), rather than opioids prescribed (e.g. written by
the provider). Earlier work suggests there is a difference between prescribed and dispensed
medications, with high rates of non-dispensing in medications prescribed by general practice
providers (Gardner, Dovey, Tilyard, & Gurr E, 1996; Lars, Nilsson, & Johansson, 1995). More
recent studies share similar findings where many prescribed medications are not actually

39

dispensed. Fischer et al. (2010) conducted an analysis of 195,930 electronic prescriptions and
found 28% of new medications prescribed by primary care providers were not dispensed.
Similarly, another study demonstrated that 31.3% of primary care patients never filled an initial
prescription (Tamblyn, Eguale, Huang, Winslade, & Doran, 2014). Though no literature exists
on perioperative opioid prescribing versus dispensing, these studies in primary care illuminate
the value of assessing opioids prescribed rather than dispensed. Measuring opioids dispensed
may underestimate actual prescribing.
Finally, there is a dearth of research evaluating the impact of the FDA warning on
codeine or opioid prescribing beyond the year 2015. Both the Chua et al. (2017) and Van Cleve
(2017) analyses are encouraging in that codeine prescribing fell as a result of the FDA warning however, in 2015 residual post-FDA codeine prescribing was shown in both studies, despite the
drug’s well documented dangers. In 2017, codeine prescribing in pediatric post-tonsillectomy
patients was 3.3% - however this reflects only one year of prescribing data (2016-2017) and does
not assess longer-term trends (Chua et al., 2019). The longer-term trend of codeine prescribing is
an important gap to fill in that the impact of FDA warnings may demonstrate erosion over time.
In a study evaluating the 2004 FDA warning on antidepressants in children, the effects of the
FDA warning differed in the early-and late-post FDA warning periods. In the years immediately
following the FDA warning, a statistically significant decline in antidepressant use was found,
but the prevalence of antidepressant use returned to pre-FDA warning levels 5 years later
(Kafali, Progovac, Shu-Yeu Hou, & Lê Cook, 2018). This suggests the impact of FDA warnings
may fade in the long-run and more frequent reinforcement of drug safety warnings may be
necessary. It is currently unknown if the effects of the FDA warning on codeine resulted in a
sustained or further reduction in codeine use and/or if alternative opioid prescribing practices
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have changed since 2015. The present study will add additional information on codeine and
opioid prescribing up to the year 2018. Overall, the current study addresses multiple gaps in the
literature by assessing post-tonsillectomy opioid prescribing in public and privately insured
children, evaluating opioids prescribed rather than dispensed and extending the study period to
understand the longer-term impact of the FDA warning.
Influence of Health Insurance on Medical Treatment
The influence of health insurance on medical treatment is complex. A review of opioid
prescribing based on insurance status and the medical treatment of publicly versus privately
insured children is presented below.
Introduction
In 2017, the CDC’s National Center for Health Statistics reported 54.7% children were
privately insured and 41.8% of children were publicly insured (Center for Disease Control,
2017). Public insurance for children via government funded programs includes Medicaid or
Children’s Health Insurance Plans (CHIP), which are based on income standards expressed as
the federal poverty level (Kaiser Family Foundation, 2018). Because only low-income families
and children are eligible for public insurance programs, children in economically disadvantaged
groups are the most likely to have government health insurance (Child Trend, 2017). Race and
ethnicity in children covered by Medicaid/CHIP tends to differ based on U.S. geography, though
in 2010 36.5% were White, 24.5% were Black, 35.7% were Hispanic and 4.3% were other/nonHispanic children (Coyer & Kenney, 2013). Private health insurance refers to plans marketed by
the private-health industry as opposed to government run insurance programs; it is primarily
provided via employee sponsored programs (Center for Medicaid & Medicare Services, n.d.). In
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2017, non-Hispanic White and Asian children were most likely to have private health insurance
whereas Hispanic children were least likely (Berchick, Hood, & Barnett, 2018).
Differences in the treatment of publicly insured versus privately insured children are
documented across many venues, including prescribing practices, access to specialty care,
hospital admissions/readmissions and healthcare utilization. Literature pertaining to opioid
prescribing practices in publicly versus privately insured children, emphasized below, is scant
and mixed; additional information on the differences in medical treatment of publicly versus
privately insured children is summarized in Table 10.
Opioid prescribing based on insurance status
A recent study from a large academic pediatric hospital assessed trends in postoperative
opioid prescribing in pediatric post-surgical patients. Donohoe and colleagues (2019) conducted
a retrospective evaluation of 65,190 pediatric outpatient surgical encounters from 2013 to 2017
and measured the rate of post-surgical opioid prescribing and duration of therapy. The
researchers found the rate of prescribing remained stable throughout the study period, though the
duration of therapy declined (p < 0.001). Certain subgroups of patients had a greater likelihood
of receiving an opioid prescription, including females (p < 0.0001) and those with public
insurance (p < 0.05). Opioids were also more likely to be prescribed in patients who did not
disclose their ethnicity and those of non-white descent (p < 0.0001). Additionally, the odds of
receiving an opioid prescription were greater for otolaryngology procedures compared with all
other procedure types (p < 0.0001). This study gives reason to believe that opioid prescribing
patterns in children undergoing tonsillectomy may differ between publicly and privately insured
children.
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However, other studies reveal that opioid prescribing is actually decreased in publicly
insured children. A cross-sectional analysis of 69,152 pediatric emergency department (ED)
patients was undertaken to evaluate factors associated with opioid prescribing. Those using
Medicaid as their primary payment method had a significantly lower likelihood of being
prescribed an opioid (OR = 0.74, 95% CI = [0.67-0.81]) compared with those using private
insurance (Tomaszewski et al., 2018). This study also revealed that white patients were more
likely to be prescribed an opioid (OR 1.34, 95% CI = [1.19-1.50]) compared with nonwhite
patients. However, this study was not conducted in the perioperative setting, limiting its
generalizability to post-tonsillectomy children.
Additionally, Fortuna and colleagues (2010) assessed prescribing rates of controlled
substances (opioids) for injury and non-injury related visits in adolescents and young adults
across multiple settings, including outpatient clinics and emergency departments. Using National
Hospital Ambulatory Medical Care Survey data from 2005 to 2007, this study showed uninsured
patients were consistently prescribed controlled substances at higher rates than those with private
insurance (p < 0.001) (Fortuna, Robbins, Caiola, Joynt, & Halterman, 2010). Though this study
does not address post-operative opioid prescribing, it further highlights prescribing differences
based on health insurance status.
Though inconsistent, the general body of knowledge indicates there are variations in
opioid prescribing patterns and one factor associated with these variations appears to be
insurance status. Plausible explanations for differences in opioid prescribing in pediatric posttonsillectomy patients may be related to implicit or explicit biases based on certain patient
characteristics or clinical reasoning, as discussed in Chapter 1.
Medical treatment based on insurance status
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Additional evidence illustrates that publicly insured children may be treated differently
than their privately insured counterparts. These studies, summarized in Table 10, collectively
represent treatment differences that may be, in part, based on insurance status.
Table 10
Treatment Differences in Publicly versus Privately Insured Children

Study
(Alexander
& Currie,
2017)

(Boss et
al., 2015)

(Bisgaier
& Rhodes,
2011)

Design & Subjects

Measures

Conclusions

Retrospective review
of children between 3
months and 13 years
of age who presented
at a New Jersey
hospital ED between
2006 and 2012
Retrospective review
of outpatient
otolaryngology clinic
children with a new
diagnosis of sleepdisordered breathing
and without a PSG
sleep study (n=136)
Prospective study of
two paired phone
calls separated by 1
month to 273
randomly selected
specialty pediatric
medical clinics in one
Midwest county

Likelihood of
hospital admission
during high fluweeks

Likelihood of hospital admission
favored privately insured children
for admission, especially when
hospitals are capacity constrained

Days from initial
evaluation to sleep
study & days from
initial evaluation to
adenotonsillectomy

Children with OSA who had
public insurance had longer
intervals from initial evaluation
to sleep study (p = 0.001) or
surgery (p = 0.001)

Ability to make an
appointment at a
specialty clinic
(eight specialty
clinics
investigated)

Significant differences in
provider acceptance of
Medicaid/CHIP versus private
insurance. Average wait time for
publicly insured children was 22
days longer (p < 0.005); 66% of
publicly insured children were
denied an appointment compared
with 11% of privately insured
children (p < 0.0001)
Total number of asthma
prescriptions possessed by
Medicaid children were higher
compared with privately insured
children (29.5% vs 12.8%; p <
0.01)

(Chang et Retrospective cohort
al., 2014) study evaluating
Medicaid (n=6,435)
& commercially
(n=4592) insured
children who newly
started asthma
treatment

Total number of
asthma
prescriptions
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(Sabharwal Retrospective evaluation Time from
initial
et al., of children < 18 years
with
an
extremity
injury
presentation to
2007)
requiring orthopedic
consultation after
visiting the ED (n= 125)

time until
orthopedic
consultation

52% of children with private
insurance received orthopedic
care within 24 hours compared
with 22% with public insurance
(p = 0.013)

The complexity of health and health care invites many alternative explanations for these
findings, including delay/avoidance of health care due to low-literacy, limited health-related
knowledge, perceptions of health care and transportation, cost or other access barriers (Arpey et
al., 2017; Smith et al., 2018; Polit & Beck, 2017). Still, health insurance status seems to
influence some aspects of health and health care, including prescribing patterns.
Theoretical Framework
The following section details the theoretical underpinnings of the study and applies the
theoretical constructs within the context of the study.
Introduction
Defining the quality of healthcare is challenging. Many problems stem from the notion
that quality is inherently difficult to define. The Institute of Medicine (IOM) initially defined
quality as “the degree to which health services for individuals and populations increases the
likelihood of desired health outcomes and are consistent with current professional knowledge”
(Institute of Medicine, 1990, p.21). Later, the IOM presented a new conceptualization of quality
to include six domains of quality healthcare – care that is safe, timely, patient-centered, effective,
equitable and efficient (Institute of Medicine, 2001).
Quality of care is a central matter in this study. Evaluating codeine and opioid prescribing
in publicly and privately insured pediatric post-tonsillectomy patients aligns with the IOM’s
quality conceptualizations of safety (halting codeine prescribing) and equity of care (in all
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children, regardless of health insurance status). The Donabedian model will serve as a
framework to define how quality will be measured in this study.
The Donabedian model
In pursuit of evaluating quality in healthcare, Avedis Donabedian worked to define and
develop techniques to measure the quality of healthcare; his research contributed an influential
body of work on the theory and practice of quality in healthcare (Ayanian & Markel, 2016). As
shown in Figure 4, Donabedian’s landmark article proposed three domains in which the quality
of healthcare can be assessed – structure, process and outcome (S-P-O) (Donabedian,
1966/2005). The assumption of the model is “good structure increases the likelihood of good
processes, and good processes increases the likelihood of good outcomes” (Donabedian, 1988,
p.1145). It is integral to note that structure, process and outcome do not themselves constitute
elements of quality – rather they are vehicles by which quality can be assessed. The following
narrative will describe each arm of Donabedian’s triad.

Figure 4. The Donabedian Model
Shi & Singh (2015) describe structure as the foundation of quality healthcare. The
structure of care relates to the organization of health care delivery and can be viewed at the
system, organizational or individual level (Kleinman & Dougherty, 2013). The structure arm of
the triad refers to characteristics or attributes of the setting in which care occurs and
instrumentalities that produce care within those settings (Donabedian, 1966/2005). Facility
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resources, qualifications of providers/organizations, administrative structure, governance systems
and fiscal components are aspects of Donabedian’s structure arm. Structure may also include
administrative and related processes that support and direct the provision of care (Shi & Singh,
2015; Donabedian, 1966/2005). The assumption, as delineated by Donabedian (1966/2005), is
“given the proper settings and instrumentalities, good medical care will follow” (p. 695).
Another approach to quality assessment is to evaluate the process of care itself. The
process arm of the triad represents what is actually done in giving and receiving care and
includes all components of delivered care (Donabedian, 1988). Performance of the healthcare
provider can be assessed by both technical and interpersonal aspects. Best practice, or the
process that is “known or believed to produce the greatest improvement in health”, is used to
judge the goodness of technical performance or effectiveness of delivered care (Donabedian,
1988, p. 1743). Interpersonal aspects of care comprise effective provider-patient communication
based on dignity, respect, compassion and concern (Shi & Singh, 2015). Again, the assumption
by Donabedian (1966/2005) is when “good” medical care has been applied, “good” outcomes
will follow. Processes can be evaluated by means of appropriateness of medical care, technical
competence, coordination of care, acceptability of care and interpersonal performance
(Donabedian, 1966/2005). Process measures are actionable (e.g. can modify a process to reflect
best practice) and can be directly targeted to improve quality (Glance, Neuman, Martinez,
Pauker, & Dutton, 2011).
Finally, the outcome of medical care is a frequently used indicator to evaluate quality of
care. It denotes the effect of care on the health status of the patient and population; its evaluation
may broadly encompass recovery, restoration of function and survival (Donabedian, 1988;
Donabedian, 1966/2005). Shi & Singh (2015) describe outcomes as final results comprising
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health status, recovery/improvement, mortality, iatrogenic illnesses, re-hospitalization, disease
incidence and prevalence and patient satisfaction. Because outcomes are relatively concrete,
valid, widely accepted and amenable to precise measurement, using outcomes as indicators of
quality is common and advantageous – so long as the outcomes are clearly defined and relevant
(Donabedian, 1966/2005). Outcomes “by and large, remain the ultimate validators of the
effectiveness and quality of medical care” (Donabedian, 1966/2005, p. 694).
The components of Donabedian’s triad were discussed distinctly to provide information
on each domain in which quality can be assessed. Yet, this approach to quality assessment is
only possible “because good structure increases the likelihood of good processes, and good
processes increase the likelihood of good outcomes” (Donabedian, 1988, p. 1145). Thus, a
unidirectional relationship exists among these elements. This relationship between S-P-O makes
Donabedian’s model a useful framework to evaluate the influence of structural and processrelated factors on outcomes. As shown in Table 11, this triad has been widely adopted and used
extensively to evaluate the quality of healthcare.
Table 11
Donabedian’s Model Applied to Evaluate the Quality of Healthcare
Study
(Hannan et
al., 2001)

Design/Population
Retrospective
review of patients
undergoing carotid
endarterectomy
(CE)
(n = 3644)

Structure
n/a

Process
Outcome
Surgical approach Death or stroke
and/or medication
administration in
patients
undergoing CE

(Gardner,
Gardner, &
O’Connell,
2014)

Mixed methods
study evaluating
nurse practitioner
(NP) services using
stakeholder surveys
(n=36) and in-

Settings for NP
services (6
service
settings)

Clinical services
provided by NP’s
(technical
competence and
scope of practice)
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Quality of care
(safety and patient
satisfaction)

(Liu,
Singer,
Sun, &
Camargo,
2011)
(Moore,
Lavoie,
Bourgeois,
&
Lapointe,
2015)
(Profit et
al., 2010)

(Tsai,
Joynt,
Orav,
Gawande,
& Jha,
2013)

depth interviews
(n=24)
Retrospective
review of patients
boarded in an
emergency
department
Retrospective
review of patients
treated in 57
trauma systems (n=
63, 971)
Synthesis of
various
frameworks of
quality of care to
form composite
indicators for
quality of care
Retrospective
review of Medicare
patients discharged
after
hospitalization for
six indexed
procedures (n=
479, 471)

Overflow of
boarded
patients to the
hallway

Delays or errors
in diagnosis or
treatment

Quality of care
(length of stay,
patient satisfaction,
adverse outcomes)

Trauma
accreditation
reports

Conformity to
established
clinical processes

Mortality, length of
stay, unplanned
readmissions,
complications

Nurse-topatient ratio,
intensivist inhouse 24 hours
per day

Medication safety Infection rates,
practices, central pneumonia rates,
line and ventilator mortality
assisted
pneumonia
processes

Hospital size,
teaching status,
region

Adherence to
surgical process
measures

Hospital
readmission rates

Application of Donabedian’s model
This study explores the linkage of Donabedian’s S-P-O constructs, as illustrated in Figure
5, where the FDA warning (structure) will lead to a change in prescribing practices (process) and
influence the number of codeine and alternative opioid prescriptions (outcome). An adaptation to
the model includes health insurance status, where health insurance status (antecedent) may affect
the number of codeine and alternative opioid prescriptions.
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Figure 5. Application of Donabedian’s Structure-Process-Outcome model
In this study, the structure arm of the triad is viewed at the system level, where the FDA
warning is an administrative/regulatory process that supports and directs the provision of care.
Prescribing practices are consistent with actual care rendered, fitting within Donabedian’s
process arm. Outcomes, or final results, are the actual number of codeine/opioid prescriptions
received by pediatric post-tonsillectomy and/or adenoidectomy patients.
The Donabedian model was modified by Coyle & Battles (1999) to include antecedent
conditions, or factors that may significantly influence the outcomes of care. Antecedent
conditions account for the patient’s environmental and/or personal characteristics – the former
includes cultural, social, political and physical aspects and the latter includes genetics, sociodemographics, health attitudes, beliefs and preferences (Coyle & Battles, 1999). Health
insurance status is described as a pertinent socio-demographic antecedent to quality health care
in Coyle & Battles’ (1999) adaptation of the model, providing justification to include health
insurance status as antecedent in this study.
Research Aims and Hypotheses
Aim 1: Evaluate post-tonsillectomy codeine prescribing in publicly and privately insured
children who underwent tonsillectomy and/or adenoidectomy at OHSU before and after the 2013
FDA warning on codeine.
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Hypothesis one (H1): In publicly and privately insured post-tonsillectomy and/or adenoidectomy
children at OHSU, rates of codeine prescribing (level and/or trend) decreased following the 2013
FDA warning on codeine.
Aim 2: Compare post-tonsillectomy codeine prescribing in publicly and privately insured
children who underwent tonsillectomy and/or adenoidectomy at OHSU before and after the 2013
FDA warning on codeine.
Hypothesis two (H2): There is a difference in codeine prescribing (level and/or trend) between
publicly and privately insured post-tonsillectomy and/or adenoidectomy children at OHSU.
Aim 3: Examine all other post-tonsillectomy opioid prescribing (oxycodone, hydrocodone) in
publicly and privately insured children who underwent tonsillectomy at OHSU before and after
the 2013 FDA warning on codeine.
Hypothesis three (H3): In publicly and privately insured post-tonsillectomy and/or
adenoidectomy children at OHSU, rates of alternative opioid prescribing (level and/or trend)
increased following the 2013 FDA warning on codeine.
Aim 4: Compare post-tonsillectomy other opioid prescribing in publicly and privately insured
children who underwent tonsillectomy and/or adenoidectomy at OHSU before and after the FDA
warning on codeine.
Hypothesis four (H4): There is a difference in other opioid prescribing (level and/or trend)
between publicly and privately insured post-tonsillectomy and/or adenoidectomy children at
OHSU.
Chapter Summary
Post-tonsillectomy adverse events result from a variety of factors including opioids,
comorbid conditions and genetic risk signatures. Codeine, and potentially other opioids, should
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be avoided in all post-tonsillectomy and/or adenoidectomy children due to the risk significant
adverse events. Studies have evaluated the impact of the FDA warning on codeine and opioids in
privately insured children, but no study has done so in publicly insured children. Though the
evidence is mixed, studies suggest insurance status may influence prescribing patterns. The
purpose of this study is to fill the research gap of codeine/opioid prescribing in publicly insured
post-tonsillectomy and/or adenoidectomy children and compare prescribing rates between
publicly versus privately insured children.
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Chapter 3: Methodology
Chapter Overview
The purpose of this study is to examine the impact of the FDA warning on codeine/opioid
prescribing in children undergoing tonsillectomy and/or adenoidectomy at Oregon Health and
Science University (OHSU) and to evaluate if prescribing practices vary based on health
insurance status. The previously described Donabedian model provides the theoretical
framework to inform the study. Donabedian’s constructs of structure, process and outcome will
guide operationalization of study variables and evaluation of study data.
Chapter Three describes the study’s research methodology, including research design,
population, and sampling information. A detailed description of the study’s variables, discussion
of the data source, overview of data collection procedures and a summary of the data analysis
plan is presented. This section concludes with an account of the validity of research design.
Research Design
This study will evaluate the impact of the FDA warning on opioid prescribing in pediatric
post-tonsillectomy patients by employing a quasi-experimental, interrupted time series (ITS)
study design. An ITS design provides understanding of patterns of change over time and
evaluates the effects of a planned or unplanned intervention (Velicer, Hoeppner, & Goodwin,
2012). The ‘time series’ represents repeated observations of a particular event collected over
time in a defined population and the ‘interruption’ signifies the intervention (Polit & Beck,
2017). The most common ITS design includes two segments where the first comprises rates of
the event prior to the intervention or policy change and the second represents the rates after the
intervention or policy change (Penfold & Zhang, 2013). Series of observations on the same
outcome can test immediate and gradual effects of the intervention or policy change (Taljaard,
McKenzie, Ramsay, & Grimshaw, 2014). This study design is particularly useful when the
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investigator does not have control over the implementation of an intervention, when
randomization is not feasible and when a control group is lacking (Penfold & Zhang, 2013; Polit
& Beck, 2017). Time series designs can be prospective or retrospective, or a combination of both
(Polit & Beck, 2017). This study will employ a retrospective design and obtain data from the
health system’s electronic health record (EHR).
An ITS design is an appropriate methodology for this study for several reasons. First, ITS
designs are the standard for evaluating the impact of policy changes, public health interventions
or quality improvement programs (Bernal, Cummins, & Gasparrini, 2017; Penfold & Zhang,
2013; Ray, 1997). The design is particularly suited to assess interventions/policies that are
instituted at a population level over a defined period of time (Bernal et al., 2017). The ITS
methodology aligns with the current study’s aim of evaluating the effects of a policy/regulatory
change (FDA warning) on repeated outcomes (prescribing practices) in a defined population
(pediatric post-tonsillectomy patients). Next, this study contains a naturally occurring
intervention (FDA warning) that represents the ‘interruption’ in the ITS design. This feature
allows for clear differentiation of pre-and post-intervention periods and repeated pre-and postintervention measures. Additionally, similar studies utilized the ITS study methodology to
evaluate opioid prescribing practices, as summarized in Table 12. Finally, it would not be
feasible nor ethical to randomize participants to intervention and control arms within the context
of the FDA warning on codeine; this warning applied nationally to all post-tonsillectomy
children immediately after the warning was announced.
Table 12
Interrupted Time Series Methodology in Opioid-prescribing Studies
Study

Objective

Data Source
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Time series comparisons

(Bohnert, Guy, If release of the 2016 CDC
& Losby, 2018) Guidelines for Prescribing
Opioids for Chronic Pain*
corresponded to declines in
opioid prescribing practices
in U.S. adults
(Boyle et al.,
If sharing individual
2019)
provider prescribing data
with other providers*
impacted the rates of opioid
prescriptions written for
adult patients discharged
from the ED
(Chua et al.,
If the FDA Boxed Warning*
2017)
on codeine resulted in a
reduction in codeine and/or
opioid prescribing in
children who underwent
tonsillectomy
(Fernandes et
al., 2016)

(Meisenberg,
Grover,
Campbell, &
Korpon, 2018)

If the national clinical
practice guidelines* and/or
drug policy interventions*
impacted opioid prescribing
rates or opioid-toxicity
hospitalizations in Canadian
citizens
If a multilevel opioid
intervention* reduced
opioid prescribing in
inpatient and outpatient
adult patients

Retail pharmacy
data from 20122017

Single center
community hospital
EHR data from
2015-2016

Prescription data
from the Truven
MarketScan
Commercial Claims
Encounters
database from
2012-2015
Prescription data
from the Ontario
Drug Benefit
database from
2003-2014
Single center
community hospital
EHR data from
2016-2018

Compared pre-and postCDC guideline monthly
prescribing measures
(dosage, supply,
opioid/benzodiazepine
overlap)
Compared pre-and postintervention number of
discharge prescriptions
written by each clinician

Compared pre-and postFDA warning codeine and
opioid prescribing rates

Compared pre-and postintervention rates of
prescribing, dose of opioid
prescribing and opioidrelated ED visits and
hospitalizations

Compared pre-and postintervention morphine
milligram equivalents
(MME) per month, MME
per prescription and rates
of opioid prescriptions
(Ranapurwala, If Iowa’s prescription
Iowa’s private
Compared pre-and post
Carnahan,
monitoring program*
health insurance
PMP daily MME dosage,
Brown,
(PMP) reduced opioid
claims database
MME per prescription,
Hinman, &
prescribing patterns in
from 2003-2014
supply of opioids and
Casteel, 2019)
adults
overall prescribing rates
(Van Cleve,
If the FDA Boxed Warning* Prescription data
Compared pre-and post2017)
on codeine resulted in a
from the Truven
FDA warning
reduction in codeine and/or MarketScan
codeine/opioid prescribing
opioid prescribing in
Commercial Claims rates and ED visits.
pediatric post-tonsillectomy Encounters
patients
database from
2012-2015
*I = “Interruption” in the design
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Data Source
The data source for this study is OHSU’s EHR platform, EPIC Hyperspace®. The
outpatient EPIC Hyperspace® platform was fully integrated into OHSU in 2008. Thus, the data
source is expected to yield complete, electronic data from 2010-2018. Data will be extracted by
the OHSU Pharmacy Informatics team; information regarding data collection is detailed below.
Population and Sample
Target population & accessible population
The target population for this study is U.S. pediatric patients up to 18 years of age
undergoing tonsillectomy and/or adenoidectomy on an outpatient basis. The accessible
population is children up to 18 years of age who presented to OHSU between January 2010
through December 2018 for outpatient tonsillectomy and/or adenoidectomy.
Sampling strategy
In retrospective evaluation of EHR data, sampling refers to the method by which cases or
records are selected from the accessible population or database. A convenience sampling method
is the most common method for selecting cases or records from an EHR over a specific time
frame (Worster & Haines, 2004). In this study, the EHR represents the sampling frame and the
sampled population will be all eligible patients who underwent tonsillectomy and/or
adenoidectomy at OHSU between January 2010 through December 2018. The number of cases
in the sample will be limited to the number of cases performed at OHSU. This convenience
sampling strategy is expected to produce adequate data, as OHSU otolaryngology surgeons
perform nearly 300-400 such cases annually.
Eligibility criteria
Inclusion and exclusion criteria are presented and justified in Table 13, below.
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Table 13
Inclusion and Exclusion Criteria
Inclusion

Exclusion

Criteria
Male or female
patient presenting for
outpatient
tonsillectomy and/or
adenoidectomy at
OHSU
Age 0-18 years

Justification
The FDA warning applies to all children undergoing
tonsillectomy and/or adenoidectomy, regardless of
demographic characteristics or indication for
tonsillectomy.

The FDA warning applies to all children < 18 years of
age.
Public or private
No study has compared post-tonsillectomy opioid
insurance
prescribing in publicly versus privately insured children.
Research suggests insurance status may impact opioid
prescribing practices (Donohoe et al., 2019).
Date of surgery
The month the FDA warning was announced (February
between February
2013) plus the month after (March 2013) will be
2013 – March 2013
excluded. Exclusion of the month/month after accounts
for a “wash out” effect (Polit & Beck, 2017).
A combined
A combined procedure of any type may influence postprocedure of any type operative pain severity may increase the likelihood of a
post-operative opioid prescription (Donohoe et al., 2019.;
Fortuna et al., 2010).
Inpatient admission
Inpatient admission allows for greater patient monitoring
following
capabilities, which may increase the likelihood a
tonsillectomy
provider would prescribe post-tonsillectomy and/or
adenoidectomy opioids.
Uninsured children
Due to federal and state initiatives, the percentage of
uninsured children in Oregon is < 3%. This low rate of
uninsured children would lead to inadequate observations
per time period and unbalanced study groups. Uninsured
children will not be included in the statistical model for
the health insurance stratified analysis.

Power analysis
In ITS, power is a function of a variety of factors including the number of time points, the
distribution of time points before and after the intervention, the degree to which data are
correlated across time (autocorrelation), expected effect size and the presence of confounders
(Bernal et al., 2017). As a result, there are no fixed limits regarding the number of time points –

57

though it has been suggested that studies with few time points and small effect sizes may be
underpowered (Bernal et al., 2017; Zhang, Wagner, & Ross-Degnan, 2011). Time points are
defined as a continuous sequence of observations on a population, taken repeatedly at equal
intervals over time; there is no standard measurement interval – weekly, monthly and yearly time
points are described in health policy literature (Bernal, Cummins, & Gasparrini, 2018; Hudson,
Fielding, & Ramsay, 2019). In ITS, power increases with the number of time points and/or if the
number of time points before and after the intervention are equally distributed. The latter is
rarely practical whereas former is imperative, as a sufficient number of time points are required
to properly analyze time-series data (Bernal et al., 2017; Wagner, Soumerai, Zhang, & RossDegnan, 2002). Power also increases when autocorrelation is small, when effect size is large and
when changes in both the regression slope and level is expected; all of these values are often
difficult to establish a priori (Zhang et al., 2011).
Using simulated-based power calculations, Zhang et al. (2011) described acceptable
methods for calculating power in health policy time-series research designs. With a significance
level of alpha (a) = 0.05, models with greater than 80% power to detect moderate effect sizes
require 24 or more time points. Samples as small as 12 time points should be used with caution
as unreliable power estimates and Type II error may be introduced (Wagner et al., 2002; Zhang
et al., 2011). In addition to a sufficient number of time points, ITS requires an adequate number
of observations at each time point (Hawley, Ali, Berencsi, Judge, & Prieto-Alhambra, 2019).
There appears to be no distinct minimum number of observations at each time point, though
>100 is desirable to achieve an acceptable level of variability at each time point (Wagner et al.,
2002). Table 14 details the components of power analysis considered for this study.
Table 14
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Components of Power Analysis
Anticipated effect size
Anticipated autocorrelation

Anticipated change in level and
slope
N= Total number of time points
(time points = months)

Small. Based on conservative estimates from the
literature (Chua et al., 2017; Van Cleve, 2017)
Unknown. If autocorrelation is unknown, using a range
of 0.1 and 0.5 is recommended. This is consistent with
previous policy evaluation time-series studies (Zhang et
al., 2011)
Based on previous studies, both a level and slope change
are anticipated, with a greater change in the level when
compared with the slope (Chua et al., 2017)
Pre-intervention: 31 time points (January 2010 – July
2012)
Post-intervention: 69 time points (April 2013 –
December 2018)
Total N = 100
25-30, assuming 300-400 tonsillectomies per year

n = Total number of observations
at each time point (observations =
number of tonsillectomies per time
point)
Balance of design
Unbalanced. The post-intervention period includes a
greater distribution of time points. Pre- and postintervention periods in health policy research are often
unbalanced (Bernal et al., 2017)
Confounders
Seasonal variation in rate of tonsillectomies may
influence power

The relatively low number of observations at each time point, unbalanced design, small
effect size and potential seasonal variation may be offset by the sufficiently long sampling period
and adequate number of time points (Polit & Beck, 2017; Wagner et al., 2002). Power is also
enhanced in this study due to population-level repeated measures of the outcome over an
extended period of time, a well-defined pre-and-post health policy change period and equally
spaced observation intervals (Hawley et al., 2019). Based on Zhang’s et al. (2011) simulated
power analysis, the estimated power for a model with both a slope and level change, a small
effect size, unbalanced pre-and post-intervention periods, autocorrelation range between 0.1-0.5
and a= 0.05, power is expected to be 0.76 – 0.99. Thus, this study is appropriately powered.
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Data Collection
The tool used to collect data in this study will be the OHSU health system’s EHR. An
EHR is unbiased (non-reactive) and inexpensive way to collect data (Polit & Beck, 2017). EHR’s
collect longitudinal, electronic data during routine delivery of health care and generally include
demographic, administrative, claims (medical and pharmacy), clinical, and patient-centered data
(Cowie et al., 2017). Collecting data via the EHR is an appropriate method given this study aims
to evaluate clinical, demographic, medical and pharmacy data that has been collected over time
during routine tonsillectomies and/or adenoidectomies.
Variables and Measures
Table 15 shows study variables that will be collected and their associated measurement.
In this study the predictor variables are the intervention (FDA Warning) and time (months preand post-FDA warning). The outcome variables include rates of codeine and other posttonsillectomy opioid prescribing. Additional demographic (age, gender, race) and clinical (OSA
status, body mass index [BMI] percentile) variables will be collected to assess group
comparability and to evaluate if prescribing is influenced by demographic or clinical factors;
health insurance payer information will be collected to assess if prescribing varies by insurance
status. Procedural data and date of surgery will be collected for each child. Note: International
Classification of Diseases, Ninth Revision, Clinical Modification (ICD-9-CM) and Procedure
Codes (ICD-10-PSC), International Classification of Diseases, Tenth Revision, Clinical
Modification (ICD-10-CM) and Procedure Codes (ICD-10-PCS) and Current Procedural Codes
(CPT) are further detailed in Appendix A.
Table 15
Study Variables and Measurement
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Variable Collected
Sleep related
breathing disorder
and/or OSA
diagnosis
Tonsillectomy
and/or
adenoidectomy
surgical procedure

Time
FDA Boxed
Warning
Age
Gender
Height
Weight
Body Mass Index
[BMI]

Measurement
ICD-9-CM* codes: 327.23 and/or 780.57
within 90 days of DOS
ICD-10-CM* codes: G47.33 and/or G47.30
within 90 days of DOS
CPT codes: 42820, 42821, 42825, 42826,
42830, 42831 and/or 42835, 42836 on DOS
ICD-9-PCS codes:28.2, 28.3 and/or 28.6 on
DOS
ICD-10-PCS codes: 0CTP0ZZ, 0CTPXZZ,
0CTQ0ZZ, 0CTQXZZ, 0C5P0ZZ, 0C5PXZZ,
0C5Q0ZZ, 0C5QXZZ, 0CBP0ZZ,
0CBPXZZ, 0CBQ0ZZ and/or 0CBQXZZ on
DOS
Date of service (month/year) associated with
CPT and/or ICD-9/10-PCS code(s) for
tonsillectomy and/or adenoidectomy
Measured using the date of the FDA warning
(February 2013) to denote pre-FDA warning
or post-FDA warning periods
Age at DOS; obtained via demographic
information
Male or female gender; obtained via
demographic information
Height in meters
Weight in kilograms
Weight in kilograms divided by the square of
height in meters

Race

Race (as defined by the CDC’s revised race
standards); obtained via demographic
information

Health insurance
status
Post-tonsillectomy
codeine prescribed
(0-2 days)

Payer information; obtained via
administrative claims
Prescription data; obtained from pharmacy
claims

If prescribed:

Dose (milligram/kilogram [mg/kg]) of codeine
prescribed
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Type of Variable
Categorical [OSA/no
OSA]
n/a – all children
included in the study
underwent
tonsillectomy and/or
adenoidectomy

Continuous
Categorical [pre or
post-FDA warning
period]
Continuous variable,
collapsed into
categorical variables
Categorical
[male/female]
Continuous
Continuous
Categorical
[underweight, normal
weight, overweight,
obese]
Categorical [0 =
American Indian,
Alaskan Native, Native
Hawaiian or Other
Pacific Islander, 1=
Asian, 2= Black, 3=
White]
Categorical
[private/public]
Continuous [rates of
codeine** prescribing,
expressed in %]
Continuous

Post-tonsillectomy
alternative opioid
prescribed (0-2
days)

Prescription data; obtained from pharmacy
claims

Continuous [rates of
other*** opioid
prescribing, expressed
in %]

If prescribed:

Dose (milligram/kilogram [mg/kg]) of alternative
opioid prescribed

Continuous

*ICD-9-CM and PCS effective until 10/1/2015; ICD-10-CM and PCS effective 10/2/2015 present
**Codeine = Includes codeine alone or any codeine-containing drug – the most common being
codeine with acetaminophen
***Other opioids = Hydrocodone, oxycodone, tramadol
Data management
All data will be extracted from OHSU’s EHR, exported to Microsoft® Excel and entered
into the IBM® Statistical Package for the Social Sciences (SPSS) statistical software.
Confidentiality of the data will be maintained through use of a password protected, encrypted
OHSU issued laptop. Any hard copies of subject information will be stored in a locked cabinet
and made accessible only to those directly involved in the study. Study records (electronic and/or
hard copy) will be made available for review only to those directly involved in the study and the
Institutional Review Boards (IRB) of OHSU and Virginia Commonwealth University (VCU).
Protection of Human Subjects
This study collects secondary data from the medical record, does not require consent and
represents no more than minimal risk to subjects. Subject information will be recorded in a
manner that the identity of the human subjects cannot readily be ascertained directly or
indirectly. Subject identifiers will be treated as confidential per the Health Insurance Portability
and Accountability ACT (HIPAA) of 1996; identifiers will not be used in published information
or disseminated otherwise.
Children are a vulnerable population addressed in the federal regulations of research
conduct (45 CFR 46 Subpart D; 21 CFR 50 Subpart D). From a regulatory perspective, this study
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falls into the “minimal risk” category and no additional protection is required beyond that of
appropriate IRB approval from OHSU and VCU, and abiding by the ethical standards of research
conduct (Welch et al., 2015).
Data Analysis
Data cleaning
After data extraction, the variables will be named and data will be cleaned using
procedures described by Tabachnick and Fidell (2013). First, descriptive statistics will be
evaluated for accuracy of data input, including assessment of normality, out-of-range values and
outliers. Next, missing data will be assessed; if data is missing, a missing value analysis will be
performed to identify the extent and pattern of missing data. Linearity between the independent
(time) and dependent (prescribing rates) variables within each regression segment will be assess
via residual plots (Wagner et al., 2002). Autocorrelation will be assessed and, if present, will be
dealt with via adjustment of standard errors as suggested by Tabachnick and Fidell (2013).
Descriptive statistics
Descriptive statistics will be generated to describe the characteristics of children
undergoing tonsillectomy at OHSU between January 2010 – December 2018. For each study
year the following will be reported: Sample size, gender (% male and female), age (% 0-4.9
years, 5-9.9 years, 10-18 years) weight status (% underweight, normal weight, overweight or
obese), race (% American Indian, Alaskan Native, or Other Pacific Islander, Asian, Black or
African American and White), health insurance status (% public and private) and OSA status (%
with and without OSA).
Time-series analysis
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Segmented regression analysis is a statistical method for modelling ITS data and will be
used in this study to assess the impact of the FDA warning on codeine and opioid prescribing in
post-tonsillectomy children. This is a well-established method to test the hypothesis that an
intervention caused a significant change in the outcome over time (Valsamis, Ricketts, Husband,
& Rogers, 2019; Wagner et al., 2002). Segmented regression is an adaptation of linear regression
where separate regressions are performed for periods before and after an intervention
(Tabachnick & Fidell, 2013; Valsamis et al., 2019). The regression coefficients of the model
estimate the pre-intervention slope, the level change at the intervention point and the slope
change from pre-intervention to post-intervention (Kontopantelis, Doran, Springate, Buchan, &
Reeves, 2015). Figure 6 further describes the slope and level changes within the context of an
ITS design.

Figure 6. Slope and Level Changes in Interrupted Time Series Designs. Information from:
(Kontopantelis et al., 2015)
The two segments in this study will be defined as the pre-FDA or post-FDA warning
periods and the intervention, or ‘interruption’, will be the FDA warning. Segmented linear
regression will quantify changes in the level and slope in the pre-and post-FDA warning periods,
then estimate if the differences are statistically significant. The level and trend estimates will
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provide information on the immediate (level change) and/or gradual (trend or slope change)
effects of the FDA warning. The segmented regression equation that will be used for this study,
adapted from Wagner et al. (2002), is: Yt= b0 + b1*timet + b2*interventiont + b3*time after +et
Where Y = mean number of prescriptions in month t
time = time in months at time t from the start of the observation period
intervention = time t occurring before or after the FDA warning
time after = number of months after the FDA warning at time t
b0 = baseline level of number of prescriptions per month at time zero
b1 = change in the mean number of prescriptions that occurs with each month preFDA warning
b2 = level change in the mean number of monthly prescriptions immediately after
the FDA warning
b3 = trend change in the mean number of monthly prescriptions after the FDA
warning, compared with the monthly trend before the FDA warning
et = error term at time t represents variation not explained by the model
The first regression model will evaluate codeine prescribing in publicly and privately
insured post-tonsillectomy children at OHSU, addressing hypothesis one (H1). The second
regression model will evaluate alternative opioid prescribing in publicly and privately posttonsillectomy children at OHSU, addressing H3. The impact of health insurance on codeine (H2)
and alternative opioid (H4) prescribing will be assessed using an additional regression model.
This model will test whether associations vary among children with public versus private
insurance. To accomplish this, interaction terms between the covariate of interest (health
insurance status) and the three ITS components relating to the pre-intervention slope, level
change, and change in slope will be evaluated (Kontopantelis et al., 2015). For all statistical tests,
p-values and confidence intervals will be reported; two-sided p-values of £ 0.05 will be
considered clinically significant. Data will also be presented graphically via time series plots.
Assumptions and Threats
The key study design assumption is that without the intervention (FDA warning), preintervention prescribing trends would continue unchanged into the post-intervention period and
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no external factors systematically affect the trends (Kontopantelis et al., 2015; Tabachnick &
Fidell, 2013). To evaluate external factors that could bias the results, the FDA’s Drug Shortages
Database (https://www.accessdata.fda.gov/scripts/drugshortages/default.cfm) will be searched to
assess for shortages of codeine, oxycodone, hydrocodone or tramadol. Also, the literature will be
examined for other interventions (known as co-interventions) that may confound the results. The
aforementioned will address the threat of history bias. Next, time series designs may exhibit
seasonal fluctuation due to cyclic variation in illnesses, preferences or clinical practice (Bernal et
al., 2018; Wagner et al., 2002). Seasonality in this study may occur related to varying rates of
tonsillectomies per month, however a sufficiently long sampling period reduces this threat.
Statistically, segmented regression assumes data are collected regularly over time at
equally spaced intervals. This assumption will be met, as the observation points in this study will
be collected at regular, monthly intervals. Also, analysis of time-series data requires that
correlation of the data points across time is accounted for (Tabachnick & Fidell, 2013; Zhang et
al., 2011). Statistical procedures will be performed to account for data points that are close
together in time and tests for autoregulation will be reported. If autocorrelation is present, it will
be controlled for statistically by adjusting the standard errors, as described by Tabachnik and
Fidell (2013). These procedures, along with an appropriate power analysis, distinct pre-and postintervention periods and accurate measurement tools, enhance the statistical conclusion validity
of this study.
Convenience sampling increases the external validity of this study, though threatens
internal validity (Polit & Beck, 2017). However, because this study observes a single population
(pediatric post-tonsillectomy patients) over an extended period of time, threats due to betweengroup differences, such as selection bias or unmeasured confounders, are minimized (Bernal et
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al., 2018). Additionally, because ITS designs model the baseline trend, within-group
characteristics that randomly fluctuate or slowly change over time are controlled for (Bernal et
al., 2018; Kontopantelis et al., 2015). Still, demographic information (age, gender, race) will be
collected and accounted for statistically if group differences are significant.
Measurement error is a potential threat in this study. This concern is reduced as no
changes in the measurement of the variables and/or data collection methods will occur.
Additionally, due to institutional and regulatory oversight, opioid prescribing is tightlycontrolled and generally free of errors. It is possible that early in the study period paper/writtenprescriptions, versus current electronic prescriptions (e-prescriptions), were prescribed.
However, all paper prescriptions were required to be entered into the EHR, minimizing this
concern. Finally, an outlier assessment will be conducted to evaluate for inconsistent data points
that may constitute measurement error.
Internal validity is also threatened due to lack of a control group. However, it is infeasible
to select a group that was not exposed to the FDA warning on codeine, as this warning applied
nationally to all children undergoing tonsillectomy. Though a control group leads to stronger
inferences, an ITS design without a control group represents a valid quasi-experimental design
(Polit & Beck, 2017).
Temporal sequencing does not pose a threat in this study as the timing of the FDA Boxed
Warning is distinct (February 2013). Pre-FDA warning outcomes (prescribing practices) will be
measured to serve as a reference point and change in the level and/or slope of the outcome in the
post-FDA warning is evidence to support temporality (Polit & Beck, 2017). The month of the
FDA warning (February 2013) and the month following (March 2013) will be excluded as a
“wash out” period.
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Chapter Summary
This chapter presented the methodological details for the study, including a description of
the planned ITS research design and data analysis methods that will be used to evaluate the
impact of the FDA warning on codeine/opioid prescribing in pediatric-post-tonsillectomy
patients at OHSU. Information regarding the sampling method, eligibility criteria, variables, data
collection and management was presented. The chapter concluded with a discussion of study
assumptions and threats to study validity. Chapter Four will present results of the study.
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Chapter 4: Results
Chapter Introduction
The dangers of codeine in children undergoing tonsillectomy and/or adenoidectomy are
well documented. Codeine prescribing should be avoided in all pediatric post-tonsillectomy
and/or adenoidectomy patients, regardless of demographic or clinical characteristics. The
purpose of this study was to examine the impact of the FDA warning on codeine/other opioid
prescribing in children undergoing tonsillectomy and/or adenoidectomy at OHSU and to evaluate
if prescribing practices vary based on health insurance status.
This study evaluated the impact of the FDA warning on opioid prescribing in pediatric
post-tonsillectomy patients by employing a quasi-experimental, interrupted time series (ITS)
design. This design provided understanding of opioid prescribing patterns over time and
evaluated the effects of the FDA warning on codeine and other opioid prescribing. This chapter
describes data preparation and statistical analyses that were employed to accomplish the study’s
aims. The chapter begins with a review of data extraction procedures, including a description of
study exclusion criteria, followed by an overview of data cleaning/preparation and statistical
assumption testing. Descriptive analysis and statistical modeling are presented. The chapter
concludes with a summary of the study findings.
Review of Data Extraction
After IRB approval from OHSU and VCU, the data was extracted from OHSU’s EHR
platform (EPIC Hyperspace®), deidentified and coded with unique patient identifiers by the
OHSU Pharmacy Informatics team. The data was transferred via email in a xls.doc (Microsoft
Excel®) following OHSU data-security protocols. Greater than 99% of opioid prescribing
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occurred within 0-2 days after tonsillectomy and therefore this prescribing interval was used.
Insurer information was confirmed for all children on the day of procedure plus two days.
The initial dataset contained 108 months (January 2010-December 2018). When the unit
of time for analysis equaled month, the total number of cases at each observation interval was
small (n < 20), potentially introducing error into the analysis and threatening validity of
inferences. Rather than monthly observations, data was grouped into 4-month observation
intervals to assure adequate observations per unit of time. Appendix B displays the months
included in each observation interval. To accommodate for the ITS analysis and to have clear
differentiation between the pre-and post-FDA warning periods, the first and last months of data
(months 1 and 108, respectively) were removed. Two months of data in time period 25 were
excluded due to outlier values, as discussed below. The month the FDA warning was issued
(February 2013) and the following month (March 2013) were excluded. Figure 7 depicts the
study exclusions. A total of 26 observation intervals were included in the analysis; observation
intervals 1-9 comprised the preintervention period and 10-26 were the postintervention period.
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Figure 7. Study Exclusion Flow Chart

Data Preparation
The data was cleaned and coded using SPSS. Study variables were coded as shown in
Table 16. Study months were ordered chronologically and coded as pre-or post-FDA warning
period. Gender was categorized as males and females. Age was collapsed into three categories
(0-4.9, 5-9.9 and 10-18 years) for clinical relevance and to approximate even groups. Though
race was recorded as White (81.3%), Multiracial (8.4%), Black (3.3%), Asian (2.4%), American
Indian (1.3%), Other Pacific Islander (0.2%) or unknown (0.1%), for analyses it was categorized
as White, Non-white or missing. Insurer was classified as public, private or self. The OHSU
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Otolaryngology billing department was consulted to assist in classifying insurers into respective
categories. Health care programs for military personnel (Tricare, ChampVA, VA Community
Outsource) represented < 2% of the sample and were included in the private insurer group. See
Appendix C for a list of insurers included in each category. Body Habitus was derived from BMI
percentile (based on age, gender, height and weight) and collapsed into normal, non-normal
(underweight, overweight or obese) or missing BMI percentile. Procedure indication denoted the
primary diagnosis associated with the procedure CPT code and was categorized as OSA versus
non-OSA. Non-OSA indications included tonsillar or/or adenoidal hypertrophy, tonsillitis,
adenoiditis and other. Opioids prescribed indicated whether a child did (yes) or did not (no)
receive an opioid prescription within 0-2 days post-tonsillectomy and/or adenoidectomy. Opioid
type included codeine-containing products or other opioids. Other opioids were non-codeine
containing products (oxycodone or hydrocodone-containing products); no children in the study
were prescribed the opioids tramadol, morphine or hydromorphone and therefore they were not
included in the variable.
Table 16
Study Variables and Coding
Variable
Study months (time)
Gender
Age
Race
Insurer

Coding
Ordered chronologically and coded as
0: Pre_FDA
1: Post_FDA
0: Males
1: Females
0: 0-4.9 years
1: 5-9.9 years
2: 10-18 years
0: White
1: Non-White
0: Public
1: Private
2: Self
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Body Habitus
Procedure Indication
Opioids Prescribed
Opioid Type

0: BMI percentile Normal
1: BMI percentile Non-Normal
2: BMI percentile Missing
0: OSA
1: Non-OSA
0: Yes
1: No
0: Codeine Containing Opioid
1: Other Opioids (Oxycodone or hydrocodone containing opioid)

Assumption Testing
Histograms with normal curve overlays for each variable were examined and are
illustrated in Appendix D. The normalized plot of residuals for each dependent variable were
inspected via Kernel Density plots and the data satisfactorily met the assumption of normality
(See Appendix E). Linearity of the preintervention trends was checked via visualization of
scatter plots. Data on the variable ‘other opioids’ met the assumption of linearity. The ‘codeine’
variable exhibited a somewhat irregular pattern in the pre-intervention period; transformations on
the variable did not markedly improve linearity. Therefore, the data was left in its original form
to retain the metrics for purposes of interpretation. Time series data inherently violate the
assumption of independence of residuals because of autocorrelation over time (Tabachnik &
Fidell, 2013). Autocorrelation of errors at various lags were examined via the Cumby-Huizinga
test for autocorrelation. Autocorrelation was present at lag 1 but not any higher order lags and,
therefore, lag(1) was included in the models. Newey-West standard errors were used in each
model to handle autocorrelation and possible heteroskedasticity. Visual inspection of time series
plots did not reveal a seasonal pattern in opioid prescribing.
The time-series plots were examined for outliers. Discrepant cases were found in time
period 25 (T25), which contained months April-July 2018. The discrepant cases were attributed
to May and June 2018, where zero opioids were prescribed during those months. Data for T25
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was re-extracted by the Pharmacy Informatics team to confirm accuracy of data extraction. The
otolaryngology surgical group verified there were no co-interventions during that time and the
pharmacy team did not find evidence of opioid shortages. The Information Technology
department confirmed an EPIC Hyperspace upgrade during that time. Given the magnitude of
discrepancy and a plausible technological fault, the outliers were dealt with via exclusion. The
remaining observations in T25 (April and July 2018) were used to populate opioid prescribing
for the observation interval. A sensitivity analysis was conducted where data from T24 was
carried forward to replace the T25 observation interval. No changes to the model occurred,
confirming the robustness of findings.
A missing values analysis was conducted. Data was complete for all variables with the
exception of race and body habitus (BMI). Because the variable race had only 3.1% missing data
and was not a critical variable for hypothesis testing, the variable was not altered. The BMI
variable contained 15% missing values. Missing values for BMI were attributed to missing
height information from the EHR. The majority of missing values occurred in the first two study
years with 65.7% and 36.3% missing in 2010 and 2011, respectively. Missingness continued to a
lesser extent throughout the remaining study years (range 4.7-12.8%). The frequency of missing
BMI percentile data is presented in Table 17. Younger children, those who were self-insured,
and children with a primary diagnosis of non-OSA tended to have higher percentages of missing
BMI percentile data. Little MCAR test was conducted on the BMI variable and showed the data
were not missing at random (Chi2 = 24.4, df =1, p = 0.00). The missing data was dealt with via
multiple imputation. Multiple imputation makes no assumptions about the type of missing data
(random or non-random) and can be applied to time-series data (Tabachnik & Fidell, 2013).
Therefore, multiple imputation was used (5 imputations) to estimate BMI from variables that
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were complete and known to predict BMI (age, gender and weight). The missing data was
replaced with the pooled results of the imputations.
Table 17
Frequency of Missing BMI Percentile Data

Gender
Age
Race

Insurance
Status
Primary
Diagnosis

Missing
N (%)
M= 467 (15.6)
F= 374 (14.4)
0-4.9 = 458 (22.2)
5-9.9 = 284 (11.5)
10-18 = 99 (9.3)
White = 705 (15.6)
Non-White= 121 (13.2)
Missing = 15 (8.8)
Public= 422 (14)
Private= 396 (15.8)
Self = 23 (24)
OSA = 481(11.3)
Non-OSA = 360 (26.7)

Descriptive Analysis
Descriptive statistics were generated for demographics, clinical characteristics and opioid
prescribing for each study year as summarized in Tables 18-20. A total of 5603 children
underwent tonsillectomy and/or adenoidectomy during the study period. On the whole, the
number of procedures increased over time. Male and female patients underwent the procedure at
similar rates. Tonsillectomy and/or adenoidectomy was most often performed in children age 59.9 years. A greater proportion of the sample were White children. Children with public or
private insurance appeared to undergo the procedure at comparable rates. Most children had a
normal body habitus. The percentage of opioid prescribing decreased over time and the trend in
the type of opioid prescribed changed with time (see Figure 8). Hydrocodone was the most
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commonly prescribed opioid in the early study period (years 1 and 2) whereas oxycodone was
more commonly prescribed in subsequent years. Codeine prescribing was low throughout the
study period, ranging from 0-3.6%. Demographic and clinical composition of the study groups
(pre-and post-FDA warning groups) will be discussed below.

Figure 8. Histogram of Study Year by Opioid Type
Table 18
Yearly Demographic Characteristics of the Sample
2010*

2011

2012

2013**

2014

2015

2016

2017

2018***

Sample
size
Gender

493

521

474

475

695

732

749

862

602

Males
N (%)
Females
N (%)

262
(53.1)
231
(46.9%)

274
(52.6)
247
(47.4)

262
(55.3)
212
(44.7)

254
(53.5)
221
(46.5)

377
(54.2)
318
(45.8)

378
(51.6)
354
(48.4)

403
(53.8)
346
(46.2)

473
(54.9)
389
(45.1)

319
(53)
283
(47)

Age
(years)
0-4.9
N (%)

175
(35.5)

219
(42)

177
(37.3)

189
(39.8)

280
(40.3)

250
(34.2)

271
(36.2)

301
(34.9)

202
(33.6)
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5-9.9
N (%)

220
(44.6)

227
(43.6)

206
(43.5)

194
(40.8)

274
(39.4)

335
(45.8)

328
(43.8)

400
(46.4)

286
(47.5)

10-18
N (%)

98
(19.9)

75
(14.4)

91
(19.2)

92
(19.4)

141
(20.3)

147
(20.1)

150
(20)

161
(18.7)

114
(18.9)

White
N (%)

406
(82.4)

434
(83.3)

391
(82.5)

394
(82.9)

567
(81.6)

601
(82.1)

605
(80.8)

667
(77.4)

450
(74.8)

Non-white
N (%)

84
(17)

81
(15.5)

78
(16.5)

73
(15.4)

110
(15.8)

107
(14.6)

112
(15)

152
(17.6)

118
(19.6)

Missing
N (%)

3
(0.6)

6
(1.2)

5
(1.1)

8
(1.7)

18
(2.6)

24
(3.3)

32
(4.3)

43
(5)

34
(5.6)

Public
N (%)

242
(49.1)

300
(57.6)

251
(53)

255
(53.7)

346
(49.8)

381
(52)

411
(54.9)

475
(55.1)

349
(58)

Private
N (%)

249
(50.5)

219
(42)

222
(46.8)

220
(46.3)

302
(43.5)

312
(42.6)

336
(44.9)

385
(44.7)

253
(42)

Self-Pay
N (%)

2
(0.4)

2
(0.4)

1
(0.2)

0

47
(6.8)

39
(5.3)

2
(0.3)

2
(0.2)

0

Race

Insurer

*Excludes January 2010
**Excludes February & March 2013
***Excludes May, June & December 2018

Table 19
Yearly Clinical Characteristics of the Sample
Body
Habitus
Original
Normal
N (%)
Non-Normal
N (%)
Missing
N (%)
Imputed
Normal
N (%)
Non-Normal
N (%)
Procedure
Indication
OSA
N (%)

2010*

2011

2012

2013**

2014

2015

2016

2017

2018***

83
(16.8)
86
(17.4)
324
(65.7)

162
(31.1)
170
(32.6)
189
(36.3)

212
(44.7)
223
(47)
39
(8.2)

227
(47.8)
200
(42.1)
48
(10.1)

325
(46.8)
281
(40.4)
89
(12.8)

391
(53.4)
303
(41.4)
38
(5.2)

389
(51.9)
325
(43.4)
35
(4.7)

422
(49)
397
(46.1)
43
(5)

300
(49.8)
266
(44.2)
36
(6)

352
(71.4)
141
(28.6)

319
(61.2)
202
(38.8)

245
(51.7)
229
(48.3)

268
(54.6)
207
(43.6)

400
(57.6)
295
(42.4)

423
(57.8)
309
(42.2)

420
(56.1)
329
(43.9)

460
(53.4)
402
(46.6)

331
(54.9)
271
(45.1)

180
(36.5)

391
(75)

371
(78.3)

388
(81.7)

543
(78.1)

590
(80.6)

594
(79.3)

710
(82.4)

490
(81.4)

77

313
130
103
Non-OSA
(63.5)
(25)
(21.7)
N (%)
*Excludes January 2010
**Excludes February & March 2013
***Excludes May, June & December 2018

87
(18.3)

152
(21.9)

142
(19.4)

155
(20.7)

152
(17.6)

112
(18.6)

Table 20
Yearly Opioid Prescribing in the Sample
2010*
2011
2012
Opioid
Prescribed
490
515
462
Yes
(99.4)
(98.8)
(97)
N (%)
3
6
12
No
(0.6)
(1.2)
(3)
N (%)
Type of Opioid
6
5
12
Acetaminophen
(1.2)
(1)
(2.5)
w/ codeine
N (%)
457
428
188
Hydrocodone/
(92.7)
(82.1)
(39.7)
acetaminophen
N (%)
27
82
262
Oxycodone
(5)
(15.7)
(55.3)
N (%)
0
0
0
Oxycodone/
acetaminophen
N (%)
*Excludes January 2010
**Excludes February & March 2013
***Excludes May, June & December 2018

2013**

2014

2015

2016

2017

2018***

445
(93.7)
30
(6.3)

605
(87.1)
90
(12.9)

651
(88.9)
81
(11.1)

655
(87.4)
94
(12.6)

741
(86)
121
(14)

499
(82.9)
103
(17.1)

17
(3.6)

18
(2.6)

21
(2.9)

1
(0.1)

5
(0.6)

3
(0.4)

114
(24)

42
(6)

35
(4.8)

39
(5.2)

2
(0.2)

0

314
(66.1)
0

544
(78.3)
1
(0.1)

595
(81.3)
0

615
(82.1)
0

733
(85)
1
(0.1)

496
(68.4)
0

Table 21 shows the demographic summaries of children in the pre-and post-FDA warning
periods. A total of 1527 tonsillectomy and/or adenoidectomy cases were performed in the preFDA warning period and 4076 were performed in the post-FDA warning period. Pearson chisquare tests for independence were used to assess for group differences in the categorical
variables of gender, age, race, insurance status, body habitus and procedure indication. There
were no differences in gender (p = 0.945), age (p = 0.110), race (p = 0.421) or insurance status (p
= 0.209) in the pre-and post-FDA periods. The distribution of body habitus and procedure
indication differed between the pre-and post-FDA warning periods. Compared with the pre-FDA
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warning period, more children had a procedure indication of OSA in the post-FDA period (p <
0.001). Also, children in the post-FDA warning period had a greater frequency of having a nonnormal BMI percentile (p < 0.001). Therefore, stratified analyses were conducted on the
subgroups of body habitus and procedure indication.
Table 21
Characteristics of the Sample in the Pre-and Post-FDA Warning Periods

Gender
Age

Pre-FDA (N=1527)

Post-FDA (N=4076)

N (%)
M=817 (53.5)
F= 710 (46.5)
0-4.9 = 591 (38.7)
5-9.9 = 668 (43.7)
10-18 = 268 (17.6)

N (%)
M=2185 (53.6)
F=1891 (46.4)
0-4.9 = 1473 (36.1)
5-9.9 = 1802 (44.2)
10-18 = 801(19.7)

Race

White = 1268 (83)
White = 3247 (79.7)
Non-White = 245 (16.1)
Non-White= 670 (16.4)
Missing = 14 (0.9)
Missing = 159 (3.9)
Insurance
Public = 811 (53.1)
Public= 2199 (53.9)
Status
Private = 711 (46.6)
Private= 1787 (43.8)
Self = 5 (0.3)
Self = 90 (2.2)
Body Habitus Normal = 939 (61.6)
Normal= 2277 (55.8)
Non-Normal= 586 (38.4)
Non-Normal= 1798 (44.2)
Procedure
OSA = 970 (63.4)
OSA = 3287 (80.6)
Indication
Non-OSA = 557 (36.6)
Non-OSA = 789 (19.4)
*Chi2 analysis, two tailed p-value set to a significance of 0.05

P-value

0.945
0.100

0.421
0.209

< 0.001*
< 0.001*

Additional comparisons were made during descriptive analysis to assess baseline opioid
prescribing in the pre-FDA warning periods. As shown in Table 22, opioid prescribing did not
appear to differ by demographic or clinical characteristics in the pre-FDA warning period. Based
on visual inspection of simple time series line plots (see Figures 9a-c), age, procedure indication
and body habitus appeared to influence opioid prescribing. Additional analytical models were
conducted to explore the impact of the FDA warning in these subgroups.
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Table 22
Opioid Prescribing in the Pre-FDA Warning Period
Pre-FDA
Opioid Y
Opioid N
P-value
Warning
(N= 1504)
(N=23)
Gender
Male
802 (98.2)
15 (1.8)
0.256
Female
702 (98.9)
8 (1.1)
Age
0-4.9 years
580 (98.1)
11 (1.9)
0.462
5-9.9 years
658 (98.5)
10 (1.5)
10-18 years
266 (99.3)
2 (0.7)
Race
White
1249 (98.5)
19 (1.5)
0.779
Non-White
241 (98.4)
4 (1.6)
Insurance
Public
803 (99)
8 (1)
0.073
Private
696 (97.9)
15 (2.1)
Procedure
Indication
OSA
957 (98.7)
13 (1.3)
0.428
No OSA
547 (98.2)
10 (1.8)
Body Habitus
BMI Normal
927 (98.6)
13 (1.4)
0.669
BMI Non-Normal 577 (98.3)
10 (1.7)
*Chi2 analysis, two tailed p-value set to a significance of 0.05

Figure 9a. Simple Time Series Plots of Opioid Prescribing in All Children & Subgroup Gender
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Figure 9b. Simple Time Series Plots of Opioid Prescribing in Subgroups Gender & Insurance Status

Figure 9c. Simple Time Series Plots of Opioid Prescribing in Subgroups Age, Procedure
Indication & Body Habitus
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Statistical Analysis
Data was imported from SPSS into Stata and analyzed in Stata using the itsa command.
An ITS analysis using segmented linear regression was used to compare opioid prescribing
before and after the FDA warning. Time periods 1-9 comprised the preintervention segment and
time periods 10-26 were the postintervention segments. The rate (percentage) of opioid
prescribing (codeine or other opioids) was used as the outcome measure. The rate of prescribing
was calculated as the number of prescriptions per time period divided by the total number of
cases per time period. Statistical models were analyzed to assess level or slope changes in opioid
prescribing over time. Additional estimates were generated from the posttrend command in
Stata. Posttrend provides estimates of the postintervention trend (b1 + b3), considering both the
preintervention trend (b1) and the difference in pre-and post-intervention trends (b3). The
posttrend estimate shows the average percentage of opioid prescribing at each interval after the
FDA warning. The coefficients of the models were estimated by ordinary least-squared
regression. The regression equation used was:
Yt= b0 + b1*timet + b2*interventiont + b3*time after +et
Where Y = mean number of prescriptions in month t
time = time in months at time t from the start of the observation period
intervention = time t occurring before or after the FDA warning
time after = number of months after the FDA warning at time t
b0 = baseline level of number of prescriptions per month at time zero
b1 = change in the mean number of prescriptions that occurs with each time period pre-FDA
warning (preintervention trend)
b2 = level change in the mean number of monthly prescriptions immediately after the FDA
warning
b3 = trend change in the mean number of monthly prescriptions after the FDA warning,
compared with the monthly trend before the FDA warning
et = error term at time t represents variation not explained by the model
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Separate ITS models were conducted for hypothesis testing. First, codeine and other
opioid prescribing in the pre-and post-FDA warning periods was assessed for the entire sample
(all children undergoing tonsillectomy and/or adenoidectomy), then subgroups were analyzed.
Subgroup analyses included insurance status, age, procedure indication and body habitus. These
subgroups were included based on the aims of the study and findings during descriptive analysis.
Opioid Prescribing in All Children
Prior to subgroup analyses, data were analyzed for opioid prescribing in all children
undergoing tonsillectomy and/or adenoidectomy during the study period. Two models were
performed: (1) Codeine prescribing (2) Other opioid prescribing in all children. Prescribing was
expressed in percentages where the number of opioid prescriptions (codeine or other opioids) per
time period was divided by the total number of cases per time period. Results are presented and
discussed below.
Codeine Prescribing in All Children

0.00

Codeine % Prescribed
1.00 2.00 3.00 4.00

5.00
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Regression with Newey-West standard errors - lag(1)

Figure 10. Time Series Graph of Codeine Prescribing in All Children
As shown in the Table 23, the starting level of codeine prescribing in all children
undergoing tonsillectomy and/or adenoidectomy was estimated at 0.97%. Codeine prescribing
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did not significantly change in the time periods prior to the FDA warning (p = 0.139). In the first
time period of the FDA warning, there was not a significant decrease in codeine prescribing (p =
0.275). The difference between the pre-and post-intervention slopes was significant (p = 0.004,
CI = [-.66, -.15]). The postintervention trend in codeine prescribing was significant and negative
(p = 0.001, CI = [-0.33, -0.14]. Figure 10 illustrates the time series graph for codeine prescribing
in all children. The predicted codeine prescribing line in the pre-intervention period did not
appear to fit the observed data well. Additional models were generated including a Newey-West
model with a linear smoother (itsa smoother) and a generalized linear model (itsa Prais). Results
were comparable and therefore the original model was retained.
These results indicate the FDA warning did not have an abrupt (level) effect on codeine
prescribing. However, a significant slope change suggests a treatment effect over time, or a
gradual downward trend in codeine prescribing after the FDA warning. After introduction of the
FDA warning, codeine prescribing decreased every time period in the post-intervention period at
a rate of 0.23%.
Other Opioid Prescribing in All Children
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Figure 11. Time Series Graph of Other Opioid Prescribing in All Children
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As shown in the Table 23, the starting level of other opioid prescribing in all children
undergoing tonsillectomy and/or adenoidectomy was estimated at 98.8%. Other opioid
prescribing appeared to decrease every time period prior to the FDA warning by 0.5% (p =
0.019, CI = [−0.92, -0.09]). In the first time period of the FDA warning, there was a significant
decrease in other opioid prescribing by 5.9% (p = 0.019, CI = [-10, -.1.0]). The difference
between the pre-and post-intervention slopes was not significant (p = 0.35). The postintervention
trend in other opioid prescribing was significant and negative (p = 0.05, CI= [-0.6, -0.01]).
Figure 11 illustrates the time series graph for other opioid prescribing in all children.
These results indicate an abrupt intervention effect (level change) rather than a gradual
treatment effect. Immediately after the FDA warning, other opioid prescribing in all children
undergoing tonsillectomy and/or adenoidectomy decreased by 5.9%. Opioid prescribing
continued to decrease by 0.31% each time interval following the FDA warning.
Table 23
Regression Table for Codeine and Other Opioid Prescribing in All Children
Variable

Coefficient

Estimates

t-statistic

P-value

Codeine
Prescribing
[All children]

b0 (Intercept)*
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

0.97
0.17
0.98
-0.40
-0.23

2.14
1.53
1.12
-3.25
-5.02

0.043
0.139
0.275
0.004**
0.001**

95% Confidence
Interval
0.03, 1.9
-0.06, 0.4
-0.83, 2.8
-.66, -.15
-0.33, -0.14

Other Opioid
Prescribing
[All children]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

98.8
-0.51
-5.95
0.19
-0.31

142.2
-2.53
-2.50
0.95
-2.12

0.000
0.019
0.02*
0.354
0.045**

97.3, 100.2
-0.92, -0.91
-10.8, -1.02
-0.23, 0.63
-0.61, -0.01

* The intercept represents the start of the data series; the p-values and/or confidence intervals are
not useful in interpretation.
**significance p £ 0.05

85

Opioid Prescribing Based on Insurance Status
To accomplish the study’s aims, ITS models were performed to evaluate opioid
prescribing in publicly and privately insured children. Self-insured children were not included in
the statistical models. Prescribing was expressed in percentages where the number of opioid
prescriptions (codeine or other) in each group per time period was divided by the total number of
cases in each group per time period. For example, codeine prescribing in publicly insured
children was expressed as: Total # of codeine prescriptions in publicly insured children per time
period (numerator) / Total # of cases in publicly insured children per time period (denominator).
Models were performed to evaluate codeine and other opioid prescribing in each group,
addressing H1 and H3. Additional models compared codeine (H2) and other opioid (H4)
prescribing between groups.
H1: Codeine Prescribing in Publicly and Privately Insured Children
The first aim of this study evaluated codeine prescribing in publicly and privately insured
children who underwent tonsillectomy and/or adenoidectomy at OHSU before and after the 2013
FDA warning on codeine and tested the following hypothesis (H1): In publicly and privately
insured post-tonsillectomy and/or adenoidectomy children at OHSU, rates of codeine prescribing
(level and/or trend) decreased following the 2013 FDA warning on codeine. Separate single
group ITS analyses were performed for codeine prescribing in publicly and privately insured
children, as presented below.
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Codeine Prescribing in Publicly Insured Children
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Figure 12. Time Series Graph of Codeine Prescribing in Publicly Insured Children
As shown in Table 24, the starting level of codeine prescribing in publicly insured
children undergoing tonsillectomy and/or adenoidectomy was estimated at 0.8%. Codeine
prescribing did not appear to change significantly in time periods prior to the FDA warning (p =
0.058). In the first time period of the FDA warning, there was no significant change in codeine
prescribing (p = 0.146). The difference between the pre-and post-intervention slopes was
significant (p = 0.003, CI = [-0.81, -0.2]). The postintervention trend in codeine prescribing was
significant and negative (p = < 0.001, CI= [-0.46, -0.15]). Figure 12 illustrates the time series
graph for codeine prescribing in publicly insured children.
These results indicate the FDA warning did not have an abrupt (level) effect on codeine
prescribing in publicly insured children. However, the slope of the regression line changed
significantly after the FDA warning, suggesting a change in the trend of codeine prescribing in
the post-FDA period. After the introduction of the FDA warning, opioid prescribing decreased
every time period in the post-intervention period at a rate of 0.3%. These results indicate a
gradual downward trend in codeine prescribing in publicly insured children.
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Codeine Prescribing in Privately Insured Children
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Figure 13. Time Series Graph of Codeine Prescribing in Privately Insured Children
As shown in Table 24, the starting level of codeine prescribing in privately insured
children undergoing tonsillectomy and/or adenoidectomy was estimated at 1.2%. Codeine
prescribing did not appear to change significantly in time periods prior to the FDA warning (p =
0.394). In the first time period of the FDA warning, there was not a significant change in codeine
prescribing (p= 0.611). The difference between the pre-and post-intervention slopes was
significant (p = 0.034, CI = [-0.64, -0.03]). The postintervention trend in codeine prescribing was
significant and negative (p = 0.006, CI= [-0.30, -0.09]). Figure 13 illustrates the time series graph
for codeine prescribing in privately insured children. The predicted codeine prescribing line in
the pre-intervention period did not appear to fit the observed data well. Additional models were
generated including a Newey-West model with a linear smoother (itsa smoother) and a
generalized linear model (itsa Prais). Results were comparable and therefore the original model
was retained.
The findings in privately insured children were similar to that of publicly insured
children. There was not an immediate (level) change in codeine prescribing in publicly insured
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children, but a significant slope change indicated a gradual reduction in codeine prescribing after
the FDA warning. The trend of the time series after the FDA warning demonstrated that codeine
prescribing decreased in privately insured children every time period in the post-intervention
period at a rate of 0.14% and the decrease was significant.
Table 24
Regression Table for Codeine Prescribing in Publicly and Privately Insured Children
Variable

Parameter

Coefficient

t-statistic

P-value

Codeine
Prescribing
[Publicly
insured]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

0.78
0.2
1.32
-0.50
-0.304

2.44
2.00
1.5
-3.41
-3.96

0.023
0.058
0.147
0.003*
< 0.001*

95% Confidence
Interval
0.12, -1.4
-0.01, 0.41
-0.5, 3.1
-0.81, -0.2
-0.46, -0.15

Codeine
Prescribing
[Privately
insured]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

1.2
0.135
0.653
-0.33
-0.19

1.61
0.87
0.52
-2.26
-4.02

0.121
0.394
0.611
0.034*
0.006*

-0.35, 2.7
-0.19, 0.46
-1.96, 3.27
-0.64, -0.03
-0.30, -0.09

*significance p £ 0.05
The hypothesis was supported. Rates of codeine prescribing decreased in the post-FDA
warning period in publicly and privately insured children. The change in codeine prescribing was
not abrupt in either group, rather both groups demonstrated a more gradual downward trend in
codeine prescribing. There was a significant slope change in codeine prescribing and significant
downward (negative) slope of the postintervention trend in both groups, indicating codeine
prescribing decreased after the FDA warning.
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H2: Codeine Prescribing in Publicly versus Privately Insured Children
Codeine Prescribing in Publicly versus Privately Insured Children
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Figure 14. Time Series Graph of Codeine Prescribing in Publicly versus Privately Insured
Children
The second aim of this study compared codeine prescribing in publicly and privately
insured children who underwent tonsillectomy and/or adenoidectomy at OHSU before and after
the 2013 FDA warning on codeine and tested the following hypothesis (H2): There is a difference
in codeine prescribing (level and/or trend) between publicly and privately insured posttonsillectomy and/or adenoidectomy children at OHSU. A multiple group ITS was performed to
compare codeine prescribing publicly and privately insured children. Additional parameters were
added to the model (b4 - b7) for group comparison:
b4: Difference in level of the outcome between treatment and control group prior to intervention
b5: Difference in slope of the outcome between treatment and controls prior to intervention
b6: Difference between treatment and control groups in the level of the outcome immediately
following the intervention
b7: Difference between treatment and control groups in the slope of the outcome after the
intervention, compared with the preintervention.
Posttrend: Difference in postintervention treatment versus control (b5 + b7)

A key assumption to a multiple group ITS is that the change in the level or trend in the
outcome variable is presumed to be the same for both groups. Parameters b4 and b5 play an
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important role in establishing balance between treatment and control groups; groups that have pvalues > 0.05 on both b4 and b5 can be used as controls in the model (Linden & Adams, 2015).
As shown in Table 25, the initial mean level and slope difference between privately and publicly
insured children were not significant (p = 0.602 and p = 0.762, respectively), indicating the
groups were comparable on baseline level and trend. There was no significant difference in
treatment effect (level change) during the first time period of the intervention (p = 0.664) and no
significant difference in pre–post trends among groups (p = 0.383). The postintervention trends
between groups did not differ (p = 0.198). Figure 14 depicts the time series graph for publicly
versus privately insured children. These results do not support the hypothesis. There does not
appear to be a difference in codeine prescribing between publicly and privately insured children
as a result of the FDA warning.
Table 25
Regression Table for Codeine Prescribing in Publicly versus Privately Insured Children
Variable

Parameter

Coefficient

t-statistic

P-value

Codeine
Prescribing
[Public versus
Private]

b4 (Baseline level)
b5 (Baseline trend)
b6 (Level difference)
b7 (Slope difference)
b5 + b7 (Post-Slope

-0.43
0.065
0.67
-0.18
-0.12

-0.52
0.35
0.44
-0.88
-1.3

0.602
0.762
0.664
0.383
0.198

95%
Confidence
Interval
-0.18, 0.45
-0.31, 0.44
-2.42, 3.76
-0.61, 0.24
-0.3, 0.06

difference)

*significance p £ 0.05
H3: Other Opioid Prescribing in Publicly and Privately Insured Children
The third aim of this study examined other opioid prescribing (oxycodone, hydrocodone)
in publicly and privately insured children who underwent tonsillectomy at OHSU before and
after the 2013 FDA warning on codeine and tested the following hypothesis (H3): In publicly and
privately insured post-tonsillectomy and/or adenoidectomy children at OHSU, rates of other
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opioid prescribing (level and/or trend) increased following the 2013 FDA warning on codeine.
Separate single group ITS analyses were performed for codeine prescribing in publicly and
privately insured children, as presented below.
Other Opioid Prescribing in Publicly Insured Children
Other Opioid Prescribing in Publicly Insured Children
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Figure 15. Time Series Graph of Other Opioid Prescribing in Publicly Children
As shown in Table 26, the starting level of other opioid prescribing in publicly insured
children undergoing tonsillectomy and/or adenoidectomy was estimated at 99.5%. Other opioid
prescribing did not change significantly in time periods prior to the FDA warning (p = 0.068). In
the first time period of the FDA warning, there was a significant decrease in other opioid
prescribing by 6.4% (p = 0.022, CI = [-11.7, -.1.0]). The difference between the pre-and postintervention slopes was not significant (p = 0.214). The postintervention trend was not
significant (p = 0.306). Figure 15 represents the time series graph for other opioid prescribing in
publicly insured children.
These results suggest an abrupt (level) treatment effect on opioid prescribing in publicly
insured children, where the FDA warning resulted in a significant and immediate reduction in
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opioid prescribing. The postintervention trend did not continue downward after the initial
reduction in other opioid prescribing, rather prescribing remained relatively flat.
Other Opioid Prescribing in Privately Insured Children
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Figure 16. Time Series Graph of Other Opioid Prescribing in Privately Children
The starting level of other opioid prescribing in privately insured children undergoing
tonsillectomy and/or adenoidectomy was estimated at 97.6% (see Table 26). Other opioid
prescribing did not significantly decrease in time periods prior to the FDA warning (p = 0.108).
In the first time period of the FDA warning, there was not a significant decrease in other opioid
prescribing (p = 0.210). The difference between the pre-and post-intervention slopes was
significant (p = 0.036, CI = [-.93, -.03]. The postintervention trend was significant and negative
(p = <0.001, CI = [-1.04, -0.5]). Figure 16 shows the time series graph of other opioid
prescribing in privately insured children.
These results indicate the FDA warning did not have an abrupt (level) change on other
opioid prescribing in privately insured children. However, a treatment effect over time (slope
change) in other opioid prescribing in privately insured children was demonstrated. After the
FDA warning, other opioid prescribing fell each time period by 0.75%.
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Table 26
Regression Table for Other Opioid Prescribing in Publicly and Privately Insured Children
Variable

Parameter

Coefficient

t-statistic

P-value

Other Opioid
Prescribing
[Publicly
Insured]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

99.5
-0.55
-6.37
0.389
-0.16

100.63
1.92
-2.47
1.28
-1.05

0.000
0.068
0.022*
0.214
0.306

95% Confidence
Interval
97.5, -101.6
-1.14, 0.44
-11.7, -1.02
-0.24,1.01
-0.48, 0.16

Other Opioid
Prescribing
[Privately
Insured]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

97.64
-0.27
-2.59
-0.48
-0.75

0.476
-1.68
-1.29
-2.23
-5.32

0.000
0.108
0.210
0.036*
<0.001*

96.65, 98.62
-0.6, 0.06
-6.8, 1.6
-0.93, -0.03
-1.04, -0.45

*significance p £ 0.05
The hypothesis was not supported; rates of other opioid prescribing did not increase
following the FDA warning. Rather, rates of other opioid prescribing decreased in both publicly
and privately insured children after the FDA warning. Interestingly, publicly insured children
saw an immediate (level) change whereas privately insured children saw a gradual (slope)
change in other opioid prescribing. Still, both groups had a significant reduction in other opioid
prescribing in the post-FDA warning period.
H4: Other Opioid Prescribing in Publicly versus Privately Insured Children
Other Opioid Prescribing in Publicly versus Privately Insured Children
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Figure 17. Time Series Graph of Other Opioid Prescribing in Publicly versus Privately Insured
Children
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The final aim of this study compared other opioid prescribing in publicly and privately
insured children who underwent tonsillectomy and/or adenoidectomy at OHSU before and after
the FDA warning on codeine and tested the following hypothesis (H4): There is a difference in
alternative opioid prescribing (level and/or trend) between publicly and privately insured posttonsillectomy and/or adenoidectomy children at OHSU.
A multiple group ITS was performed to compare other opioid prescribing in publicly and
privately insured children. As discussed above, additional parameters (b4 - b7) were added to the
model and coefficients b4 and b5 were assessed to assure comparable baseline estimates between
groups. As shown in Table 27, the initial level and slope difference between publicly and
privately insured children were not significant (p = 0.271 and p = 0.898, respectively), indicating
the groups were comparable on baseline level and trend. There was no significant difference in
treatment effect (level change) during the first time period of the intervention (p = 0.103) and no
significant difference in pre–post trends among groups (p = 0.088). The difference in the trend of
the time series after the FDA warning was significant (p = 0.007, CI = [0.71, 1.1]). However, this
can be explained by the manner in which other opioid prescribing decreased in each group.
Publicly insured children demonstrated and immediate (level) change followed by a relatively
flat trend, whereas privately insured children demonstrated a slower downward trend in other
opioid prescribing. Figure 17 illustrates the time series graph for other opioid prescribing in
publicly and privately insured children.
The hypothesis was not supported. Though there was a difference in the manner in which
opioid prescribing changed (level versus trend), other opioid prescribing decreased in both
publicly and privately insured children after the FDA warning.
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Table 27
Regression Table for Other Opioid Prescribing in Publicly versus Privately Insured Children
Variable

Parameter

Coefficient

t-statistic

P-value

Other Opioid
Prescribing
[Public and
Private]

b4 (Baseline level)
b5 (Baseline trend)
b6 (Level difference)
b7 (Slope difference)
b5 + b7 (Post-Slope

1.31
-0.04
-5.37
0.63
0.59

1.11
-0.13
-1.66
1.74
-2.8

0.271
0.898
0.103
0.088
0.007*

95%
Confidence
Interval
-1.1, 3.6
-0.69, 0.61
-11.9, 1.14
-0.1, 1.4
0.17, 1.1

difference)

*significance p £ 0.05
Additional Analyses: Age, Procedure Indication & Body Habitus
Descriptive analysis suggested that age, procedure indication and body habitus may
influence opioid prescribing in children undergoing tonsillectomy. Additional models were
performed for each variable. Results are presented and discussed below.
Opioid Prescribing Based on Age
As shown in Table 28, pre-intervention rates of codeine prescribing in children age 0-4.9
years was estimated at 2.4%. Codeine prescribing in children age 0-4.9 years decreased after the
FDA warning, evidenced by a significant slope change in the post-intervention period when
compared with the preintervention period (p = 0.012, CI = [-1.5, -0.23]). In the postintervention
period, codeine prescribing in children age 0-4.9 years decreased by 0.53% with each time
period following the FDA warning (p = 0.001, CI = [-0.8, -0.3]). However, codeine prescribing
in children age 5-9.9 and 10-18 years did not significantly decrease after the FDA warning (no
level or slope change). This is likely due to very low pre-intervention codeine prescribing rates in
these age subgroups. Pre-intervention codeine prescribing rates were 0.41% in children 5-9.9
years and nearly 0% in children 10-18 years.
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Table 28
Regression Table for Codeine Prescribing Based on Age
Variable

Parameter

Coefficient

t-statistic

P-value

Codeine
[0-4.9 years]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

2.4
0.38
2.11
-0.91
-0.53

1.65
1.2
0.9
-2.75
-4.7

0.114
0.241
0.380
0.012*
0.001*

95% Confidence
Interval
-0.63, 5.4
-0.28, 1.04
-2.8, 7.0
-1.5, -0.23
-0.8, -0.3

Codeine
[5-9.9 years]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)

0.41
-0.38
0.86
-0.008

0.94
-0.54
1.79
-0.12

0.358
0.521
0.088
0.908

-0.49, 1.3
-0.16, 0.08
-0.14, 1.85
-0.15, 0.13

Codeine
[10-18 years]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)

0.002
-0.001
0.205
-0.009

0.68
-0.69
0.98
-0.79

0.507
0.495
0.340
0.437

-0.005, 0.009
-0.005, 0.01
-0.23, 0.64
-0.033, 0.015

*significance p £ 0.05
Other opioid prescribing in children age 0-4.9 was estimated at 98.9% (see Table 29).
Other opioid prescribing abruptly decreased (level change) by 11.9% after the FDA warning (p =
0.03, CI = [-2.7, 1.04]). Other opioid prescribing in the preintervention period in children age 59.9 was estimated at 97.9%. Other opioid prescribing in this age group (5-9.9 years) did not
abruptly decrease after the FDA warning, but a significant slope change suggests a gradual
decrease in other opioid prescribing in the post-FDA warning period (p = 0.017, CI = [-0.86, 0.09]. Other opioid prescribing was estimated at 99.8% for children age 10-18 years. Children in
this age group did not experience a significant level or slope change in other opioid prescribing
in the post-FDA warning period.
Overall, it appears that the FDA warning had the most profound effect on codeine and
other opioid prescribing in the youngest children (0-4.9 years). Figure 18 shows the time series
graphs (codeine and other opioids) for children age 0-4.9 years. Children age 5-9.9 demonstrated
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gradual changes in other opioid prescribing, but no change in codeine prescribing. The oldest
children (age 10-18) did not demonstrate changes in codeine or other opioid prescribing.
Table 29
Regression Table for Other Opioid Prescribing Based on Age
Variable

Parameter

Coefficient

t-statistic

P-value

Other Opioids
[0-4.9 years]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)

98.9
-1.19
-11.87
0.54

41.8
-2.09
-2.27
0.93

0.00
0.05*
0.03*
0.364

95% Confidence
Interval
94.01, 103.8
-2.34, -0.01
-2.7, -1.04
-0.66, 1.73

Other Opioids
[5-9.9 years]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)

97.9
0.085
2.06
-0.47

92.89
0.51
-1.67
-2.57

0.000
0.618
0.109
0.017*

95.8, 100.2
-0.26, 0.43
-4.6, -0.5
-0.85, -0.09

Other Opioids
[10-18 years]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)

99.8
-0.14
-0.41
-0.02

120.5
-0.63
-0.22
-0.10

0.00
0.536
0.829
0.925

98,1, 101.5
-0.58, 0.31
-4.3, 3.5
-0.53, 0.48

*significance p £ 0.05
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Figure 18. Time Series Graphs of Codeine and Other Opioid Prescribing in Children Age 0-4.9
years
Opioid Prescribing Based on Procedure Indication
Codeine prescribing in children with OSA was estimated at 0.9% in the preintervention
period (see Table 30). Codeine prescribing did not significantly decrease in the time periods
98

prior to the FDA warning (p = 0.086). After the FDA warning, there was not a significant level
change (p = 0.099). However, a significant postintervention slope change (compared to the
preintervention slope) indicated a gradual reduction in codeine prescribing after the FDA
warning (p = 0.004, CI = [-0.68, -0.15]). Findings were similar for codeine prescribing in
children without OSA, where the FDA warning did not appear to abruptly decrease codeine
prescribing (p = 0.729), but a slope change indicated a gradual reduction in codeine prescribing
in the post-FDA warning period (p = <0.05, CI = [-1.13, -0.12]. When children with and without
OSA were compared, there were no differences in the level (p = 0.928), slope (p = 0.963) or
postintervention trends (p = 0.847) of codeine prescribing.
Table 30
Regression Table for Codeine Prescribing Based Procedure Indication
Variable

Parameter

Coefficient

t-statistic

P-value

Codeine
Prescribing
[OSA]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

0.9
0.19
0.80
-0.41
-0.22

1.8
1.73
0.83
1.8
-3.69

0.086
0.099
0.413
0.004*
0.0013*

95% Confidence
Interval
-0.13, 0.42
-0.38, 0.42
-1.2, 2.8
-0.68, -0.15
-0.35, -0.1

Codeine
Prescribing
[No OSA]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

0.06
0.33
0.62
-0.57
-0.24

0.05
1.21
0.35
-2.12
-4.07

0.964
0.283
0.729
0.046*
0.005*

-2.4, 2.55
-0.23, 0.9
-3.04, 4.2
-1.13, -0.12
-0.36, -0.12

Codeine
Prescribing
[OSA versus no
OSA]

b4 (Baseline level)
b5 (Baseline trend)
b6 (Level difference)
b7 (Slope difference)
b5 + b7 (Post-Slope

0.84
-0.14
-0.18
0.16
0.016

1.21
-0.48
0.09
0.05
0.195

0.23
0.631
0.928
0.963
0.847

-0.22, 0.89
-0.74, 0.45
-3.87, 4.2
-2.36, 2.48
-0.15, 0.18

difference)

*significance p £ 0.05
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Other opioid prescribing in the preintervention period in children with OSA was
estimated at 98.4% (see Table 31). Other opioid prescribing did not decrease significantly in the
pre-intervention period (p = 0.062). After the FDA warning, there was an abrupt decrease in
other opioid prescribing by 6.2% in children with OSA (p = 0.016, CI = [-11.2, -1.3]. The
postintervention trend (relative to the preintervention trend) was not significant (p = 0.273)
These findings indicated an immediate treatment effect in other opioid prescribing in children
with OSA. The postintervention trend estimate was not significant suggesting that after the
immediate reduction in other opioid prescribing, prescribing remained relatively flat.
In children without OSA, other opioid prescribing in the preintervention period was
estimated at 99.5%. Other opioid prescribing decreased significantly each time period in the preintervention period by 0.9% (p = 0.009, CI = [-1.6, -0.3]. After the FDA warning, there was not a
significant level or slope change. However, the postintervention trend was significant and
negative (p = 0.038, CI = [-1.9, -.42]. Other opioid prescribing in children without OSA
decreased by 1.2% each time period after the FDA warning.
When other opioid prescribing in children with and without OSA was compared (see
Figure 19), there was no difference in the immediate treatment effect (level) or differences in the
pre-and postintervention slopes. However, there was a significant difference in the postintervention estimates. Other opioid prescribing decreased in children with OSA by 0.12% in
each time period after the FDA warning whereas other opioid prescribing in children without
OSA decreased by 1.2% (p = 0.01, CI = [0.7, 1.8]). After the immediate reduction in other opioid
prescribing in children with OSA, prescribing remained relatively flat whereas the time series
trend after the intervention continued to decrease for children without OSA.
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Figure 19. Time Series Graph of Other Opioid Prescribing in Children with and without OSA
Table 31
Regression Table for Other Opioid Prescribing Based on Procedure Indication
Variable

Parameter

Coefficient

t-statistic

P-value

Other Opioid
Prescribing
[OSA]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

98.4
-0.35
-6.2
0.24
-0.11

153.3
-1.97
-2.60
1.12
-0.71

0.00
0.062
0.016*
0.273
0.483

95% Confidence
Interval
97.1, 99.7
-0.73, 0.02
-11.2, -1.3
-0.2, 0.68
-0.45, 0.22

Other Opioid
Prescribing [no
OSA]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

99.5
-0.93
-3.16
-0.44
-1.18

93.43
-2.87
-0.85
-1.21
-3.23

0.00
0.009*
0.403
0.238
0.004*

97.3, 101.7
-1.6, -0.3
-10.9, 4.5
-1.2, 0.31
-1.9, -0.42

Other Opioid
Prescribing
[OSA versus no
OSA]

b4 (Baseline level)
b5 (Baseline trend)
b6 (Level difference)
b7 (Slope difference)
b5 + b7 (Post-Slope

-1.09
0.57
-3.83
0.68
1.06

-0.88
1.54
-0.7
1.62
2.67

0.385
0.130
0.489
0.113
0.01*

-3.6, 1.4
-0.18, 1.3
-11.9, 5.8
-0.16, 1.5
0.26, 1.8

difference)

*significance p £ 0.05
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Opioid Prescribing Based on Body Habitus
Codeine prescribing in children with normal body habitus was estimated at 0.72% in the
preintervention period (see Table 32). Codeine prescribing did not appear to decrease
significantly in the preintervention period (p = 0.341), nor did it abruptly decrease after the FDA
warning (p = 0.157). However, a significant slope change in codeine prescribing indicated a
gradual reduction in codeine prescribing in the post-FDA warning period (p = 0.018, CI = [-0.89,
-.0.1]). Findings were similar in children with non-normal body habitus. Codeine prescribing in
children with non-normal body habitus was estimated at 1.1% in the preintervention period.
Codeine prescribing did not decrease significantly in the preintervention period, nor did it
abruptly decrease after the FDA warning. However, a significant slope change in codeine
prescribing indicated a gradual reduction in codeine prescribing in the post-FDA warning period
(p = 0.001, CI = [-0.48, -.1.62]).
When codeine prescribing was compared in children with normal versus non-normal
body habitus, there was no difference in the level (p = 0.949), slopes (p = 0.382) or
postintervention trend estimates (p = 0.678). Codeine prescribing did not appear to differ in
children with normal versus non-normal body habitus.
Table 32
Regression Table for Codeine Prescribing Based on Body Habitus
Variable

Parameter

Coefficient

t-statistic

P-value

Codeine
Prescribing
[Normal BMI]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

0.72
0.26
0.78
-0.49
-0.23

0.97
1.47
0.61
-2.55
-3.52

0.341
0.157
0.551
0.018*
0.002*

95% Confidence
Interval
-0.82, 2.26
-0.11, 0.64
-1.89, 3.45
-0.89, -0.1
-0.36, -0.1

Codeine
Prescribing

b0 (Intercept)
b1 (Pre-Slope)

1.1
0.1

3.83
1.04

0.001
0.311

0.48, 1.62
-0.10, 0.30
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[Non-Normal
BMI]

b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

0.89
-0.3
-0.2

1.01
-2.93
-5.9

0.325
0.001*
<0.001*

-0.94, 2.7
0.48, 1.62
-0.27, -0.13

Codeine
Prescribing
[Normal versus
Non-Normal
BMI]

b4 (Baseline level)
b5 (Baseline trend)
b6 (Level difference)
b7 (Slope difference)
b5 + b7 (Post-Slope

-0.33
0.16
-0.3
-0.19
-0.03

-0.42
0.80
1.56
-0.88
-0.41

0.306
0.427
0.949
0.382
0.687

-0.09, 0.29
-0.25, 0.57
-3.2, 3.0
-0.63, 0.25
-0.17, 0.12

difference)

*significance p £ 0.05
Other opioid prescribing in children with normal body habitus was estimated at 99.7%
(see Table 33). Other opioid prescribing decreased by 0.8% in each time period in prior to the
FDA warning (p = 0.028, CI = [-1.49, -0.1]. There was not a significant level or slope change,
however the trend of the time series after the intervention shows a significant reduction in other
opioid prescribing by 0.5% in each time period after the FDA warning (p = 0.003, CI = [-0.76, 0.26]). In children with non-normal body habitus, other opioid prescribing was estimated at
97.2% in the preintervention period and did not appear to change significantly in the time periods
prior to the FDA warning (p =0.202). After the FDA warning, other opioid prescribing abruptly
decreased (level change) by 6.88% (p = 0.022, CI = [-12.6, -1.1]). The postintervention slope,
when compared with the preintervention slope, was not significant (p = 0.894). These results
indicate an immediate rather than a delayed treatment effect in other opioid prescribing in
children with non-normal body habitus.
Other opioid prescribing did not appear to differ in children with normal versus nonnormal body habitus, however because of differences in baseline level (b4) and slope (b5) group
comparisons may be biased and are not adequate for comparison.
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Table 33
Regression Table for Other Opioid Prescribing Based on Body Habitus
Variable

Parameter

Coefficient

t-statistic

P-value

Other Opioid
Prescribing
[Normal BMI]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

99.74
-0.8
-5.12
0.28
-0.51

87.83
-2.35
-1.95
0.82
-4.23

0.000
0.028*
0.063
0.422
0.003*

95% Confidence
Interval
97.38, 102.1
-1.49, -0.1
-10.55, 0.31
-0.43, 0.99
-0.76, -0.26

Other Opioid
Prescribing
[Non-Normal
BMI]

b0 (Intercept)
b1 (Pre-Slope)
b2 (Level change)
b3 (Slope change)
b1 + b3 (Post-Slope)

97.2
-0.1
-6.88
0.03
-0.07

244.7
-1.32
-2.47
0.14
-0.31

0.000
0.202
0.022*
0.894
0.76

96.4, 98
-0.26, 0.06
-12.64, -1.11
-0.42, 0.48
-0.54, 0.4

Other Opioid
Prescribing
[Normal versus
Non-Normal
BMI]

b4 (Baseline level)
b5 (Baseline trend)
b6 (Level difference)
b7 (Slope difference)
b5 + b7 (Post-Slope

2.55
-0.69
1.75
0.25
-0.44

2.12
-2.0
0.46
0.62
-1.72

0.04*
0.05*
0.648
0.541
0.09

0.12, 4.9
-1.39, 0.005
-5.9, 9.45
-0.57, 1.1
-0.92

difference)

*significance p £ 0.05
Summary of Findings
After the FDA warning, codeine and other opioid prescribing decreased in the entire
sample. Interestingly, codeine prescribing gradually decreased over time whereas an immediate
treatment effect was demonstrated in other opioid prescribing. Varying times of the treatment
effect (immediate versus delayed) was commonly seen when analyzing subgroups. All subgroups
demonstrating a reduction in codeine prescribing in the post-FDA warning period showed a
gradual treatment effect. Other opioid prescribing decreased immediately in some subgroups,
whereas it fell more gradually in others.
Codeine and other opioid prescribing did not appear to be influenced by health insurance
status. Both publicly and privately insured children demonstrated a reduction in codeine and

104

other opioids after the FDA warning period. Decreases in codeine prescribing in both publicly
and privately insured children were gradual and there were no differences in codeine prescribing
when groups were compared. The timing of the treatment effect differed between groups when
considering other opioid prescribing. An immediate change in other opioid prescribing was
demonstrated in publicly insured children and a more gradual decrease in other opioid
prescribing occurred in privately insured children.
Age appeared to influence codeine and other opioid prescribing with the most notable
impact on the youngest children in the sample. A gradual reduction in codeine prescribing and an
immediate fall in other opioid prescribing were found in children age 0-4.9 years. Other opioid
prescribing fell gradually in the post-FDA warning period in children age 5-9.9 years, but
codeine prescribing did not change significantly in this age group. Neither codeine or other
prescribing changed significantly in the oldest children in the sample (age 10-18 years).
Children with a procedure indication of OSA or non-OSA demonstrated similar and
gradual reductions in codeine prescribing after the FDA warning. Both groups saw a reduction in
other opioid prescribing, but differed in terms of timing of the treatment effect. Children with
OSA showed an immediate decrease in other opioid prescribing after the FDA warning; after this
immediate reduction, other opioid prescribing remained relatively flat in the postintervention
period. Children without OSA demonstrated a more gradual reduction in other opioid prescribing
after the FDA warning; the post intervention trend in this group continued to decrease each time
period after the FDA warning.
Finally, children with normal or non-normal body habitus demonstrated similar and
gradual reductions in codeine prescribing after the FDA warning. Again, both groups had a
reduction in other opioid prescribing, but differed in terms of timing of the treatment effect.
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Other opioid prescribing fell gradually in children with normal body habitus, whereas children
with non-normal body habitus demonstrated an immediate decrease in other opioid prescribing.
Chapter Summary
This chapter presented the descriptive and statistical analysis of the study. Using an ITS
study design, patterns of opioid prescribing in children undergoing tonsillectomy and/or
adenoidectomy were evaluated. The primary questions of this study sought to assess if health
insurance status influenced opioid prescribing. Findings of this study revealed that both publicly
and privately insured children saw significant reductions in codeine and/or other opioid
prescribing after the FDA warning. Additional findings of interest included the effect of age,
procedure indication and body habitus on opioid prescribing. Of these, young age appeared to
influence prescribing to the greatest degree. Chapter Five will discuss the theoretical and
practical implications of the results, limitations of the study and recommendations for future
research.
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Chapter 5: Discussion
Chapter Introduction
This chapter reviews the study findings and explores the practical and theoretical
implications of the findings. A brief synopsis of the study purpose, methodology and analyses
are presented. Limitations are discussed and the chapter concludes with recommendations for
future research.
Summary and Overview of the Problem
Tonsillectomy, with or without adenoidectomy, is one of the most commonly performed
pediatric surgeries in the U.S. (Baugh et al., 2011). The procedure and care of a child undergoing
tonsillectomy and/or adenoidectomy is fairly routine – however, reports of deaths and near
deaths highlight the significant complications that can occur in children undergoing the
procedure. Many complications are related to medications that depress the respiratory drive, such
as opioids. Opioids provide post-tonsillectomy analgesia, but they also lead to unwanted effects
such as sedation and respiratory depression. Clinical and/or genetic risk factors further heighten
the danger of post-tonsillectomy opioids. Obstructive sleep apnea (OSA) belongs to the
continuum of sleep related breathing disorders and is a common indication for tonsillectomy
and/or adenoidectomy. Children with OSA are sensitive to the respiratory depressant effects of
opioids and experience a higher preponderance of perioperative adverse events (De Luca Canto
et al., 2015; Goldman et al., 2013; Mitchell et al., 2019). Obesity, which increases the likelihood
of developing OSA, also heightens a child’s risk of perioperative complications (Cote et al.,
2018; Patino et al., 2013). Additionally, it is well established that polymorphisms in the genes
responsible for codeine metabolism contributed to several post-tonsillectomy and/or
adenoidectomy deaths (Cote et al., 2014). As a result, the FDA contraindicated the use of
codeine in all children undergoing the procedure by placing a Boxed Warning on the drug. The
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2013 FDA warning advised health care professionals “to prescribe an alternative analgesic [to
codeine] for postoperative pain control in children undergoing tonsillectomy and/or
adenoidectomy” (U.S. FDA Drug Safety Communications, 2013).
Recent analyses found a significant reduction in post-tonsillectomy and/or
adenoidectomy codeine prescribing following the FDA warning, however these studies were
conducted on a sample of children with private insurance (Chua et al., 2017; Van Cleve, 2017). It
is unknown to what extent the FDA warning impacted codeine and alternative opioid prescribing
rates in publicly insured children. Examining this problem in the context of an understudied
population (publicly insured children) was important for two reasons. First, when compared to
children with private insurance, rates of tonsillectomy and/or adenoidectomy are similar for
children insured by Medicaid (Boss et al., 2012). Second, differences in opioid prescribing
between publicly and privately insured children are documented (Donohue et al., 2019;
Tomaszewski et al., 2018). Therefore, understanding prescribing behaviors in both publicly and
privately insured children fills an important gap in the literature.
Purpose of the Study and Research Questions
The purpose of this study was to investigate the relationship between the FDA warning
and codeine/alternative opioid prescribing in publicly and privately insured children who
underwent tonsillectomy and/or adenoidectomy at OHSU between 2010 – 2018. This study
sought to answer two research questions: (1) What is the relationship between the FDA warning
and codeine/alternative opioid prescribing in children who underwent tonsillectomy at Oregon
Health and Science University (OHSU) between January 2010-December 2018? (2) Does the
relationship between codeine and/or alternative opioid prescribing in pediatric post-tonsillectomy
children who underwent tonsillectomy at OHSU between January 2010 and December 2018 vary

108

by health insurance status? Results of this study clarified the impact of the FDA warning on
codeine/other opioid prescribing and compared prescribing between publicly and privately
insured children.
Review of Theory
The Donabedian model served as the framework for the study. Donabedian’s landmark
article proposed three domains in which the quality of medical care can be assessed – structure,
process and outcome (Donabedian, 1966/2005). The assumption of the model is that “good
structure increases the likelihood of good processes, and good processes increase the likelihood
of good outcomes” (Donabedian, 1988, p.1145). In this study, the structure arm of the triad was
the FDA warning, the process arm was opioid prescribing practices and the outcome was the
number of codeine/other opioid prescriptions prescribed before and after the FDA warning.
Building on Donabedian’s theory, Coyle & Battles (1999) advocated that antecedent conditions,
or personal and/or environmental factors that may influence the outcomes of care, be
incorporated into the model. In this study, health insurance status was included as an antecedent
condition that may influence opioid prescribing.
Review of Methodology
A quasi-experimental, interrupted time series (ITS) study design was used to assess
opioid prescribing before and after the FDA warning. This study included two time-series
segments and one interruption. The pre-FDA warning period was the first time-series segment,
the interruption was the FDA warning and the second time-series segment was the post-FDA
warning period. The ITS methodology facilitated an understanding of prescribing patterns over
time and evaluated the immediate and gradual effects of the FDA warning on codeine/other
opioid prescribing.
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Following IRB approval from VCU and OHSU, data was extracted from OHSU’s EHR
(Epic Hyperspace®). The sample included children who underwent tonsillectomy and/or
adenoidectomy at OHSU from 2010-2018. The data was cleaned, coded into categories (age,
gender, race, insurance status, OSA status and body habitus) and prepared for analysis.
Descriptive analysis was undertaken to provide basic information of the sample and to highlight
potential relationships between variables. Statistical analysis addressed prescribing practices in
all children and subgroups of interest, addressing all study hypotheses.
Review of Study Findings and Application to the Literature
Descriptive Findings
Several noteworthy findings during descriptive analysis were discovered. First, the trend
of opioid prescribing changed throughout the study years where a progressive decline in the
percentage of children who received any opioid following tonsillectomy and/or adenoidectomy
was demonstrated. A decrease in the percentage of children who were prescribed opioids
occurred between 2013 and 2014, coinciding with the FDA warning; this will be further explored
below. Additionally, the type of opioid prescribed changed over the study period. Hydrocodone
was the most commonly prescribed opioid early in the study period (years 2010 and 2011) and
prescribing continued modestly through 2013. Hydrocodone prescribing fell substantially in
2014, corresponding with two events: (1) the U.S. Drug Enforcement Agency and Department of
Justice’s rescheduling of hydrocodone products from Schedule III to Schedule II and (2) the
FDA warning on codeine. Drug scheduling of opioids denotes their abuse potential (lowest abuse
potential with Schedule IV and highest with Schedule I) – though scheduling also enables or
prohibits providers to refill controlled substances (U.S. Department of Justice, 2014). The
reduction in hydrocodone prescribing may be reflective of its scheduling change – however,
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another plausible explanation exists. Like codeine, hydrocodone is a prodrug and requires
substantial metabolism by the CYP2D6 enzyme to produce its active form (hydromorphone).
Though there is insufficient information to understand whether different CYP2D6 phenotypes
influence hydrocodone’s metabolism (and a dearth of case reports about pediatric
overdose/toxicity with hydrocodone), it’s plausible that providers elected to avoid prescribing
drugs that may demonstrate CYP2D6 phenotypic variability in drug metabolism. After 2014,
oxycodone-containing products (which do not rely as substantially on CYP2D6 metabolism)
became the most frequently prescribed opioid for pediatric post-tonsillectomy patients at OHSU.
Interestingly, other studies found hydrocodone to be the opioid most frequently prescribed in the
post-FDA warning era (Goldman et al., 2018; Chua et al., 2017; Van Cleve, 2017). These
differences may be related to provider or institutional preferences.
Several demographic characteristics of the sample merit elaboration. First, the majority of
the sample included children in the youngest or middle-age categories (age 0-4.9 and 5-9.9 years,
respectively). This is consistent with prior studies (Boss et al., 2012) and logical when
considering the incidence of OSA peaks between 2-8 years of age (Patino et al., 2013). Next,
similar to other age-related studies, there was an incidental finding of an increase in OSA and
non-normal body habitus over time. The percentage of children with OSA increased steadily
from 2010-2018 and the percentage of children with a non-normal body habitus was greater in
the post-FDA warning period. Finally, consistent with prior studies, this study demonstrated that
tonsillectomy and/or adenoidectomy was performed at the same rate regardless of gender or
insurer status (Boss et al., 2012).
Statistical Analysis
Opioid Prescribing in All Children
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Before hypothesis testing, codeine/other opioid prescribing was analyzed in the entire
sample. Other opioid prescribing fell abruptly after the FDA warning, yet codeine prescribing
fell more gradually. This is in contrast to other similar studies, where codeine prescribing fell
abruptly and other opioid prescribing slightly increased following the FDA warning (Chua et al.,
2017; Van Cleve, 2017). In this present study, codeine prescribing appeared to increase in the
time periods preceding the FDA warning and remained unchanged or slightly higher in the time
periods immediately following the FDA warning – thereafter, codeine prescribing began to fall.
The reasons behind this are unclear and difficult to explain clinically or empirically. Observing
changes in outcomes prior to a treatment is consistent with an “anticipation effect” (Malani &
Reif, 2015) – however it would be assumed that providers would decrease (not increase) codeine
prescribing in anticipation of the FDA warning. It is plausible that prescribing providers were
unaware of the FDA warning – or were aware, yet initially disregarded the warning. Also, if
providers did not observe codeine-related adverse events based on their prior experience with the
drug, it is conceivable they were skeptical of the FDA warning. Gathering further evidence to
substantiate the aforementioned was difficult. Given the study site was an academic health center
in a large metropolitan area, it is likely information on the FDA warning was disseminated to
prescribing providers. Thus, it is plausible that one or more providers did not initially change
prescribing practices, explaining the slower decline in codeine prescribing following the FDA
warning.
Also, Chua et al. (2017) and Van Cleve (2017) found other opioid prescribing slightly
increased following the FDA warning on codeine. In contrast, this present study found a
significant decrease in other opioid prescribing in the post-FDA warning period. It’s conceivable
that providers in this study reduced prescribing of other opioids (oxycodone and hydrocodone)
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because they are stronger, higher-potency opioids with a greater perceived risk of adverse events.
Also, rather than relying on opioids for post-tonsillectomy pain, providers may have responded
to the FDA warning by incorporating non-opioid agents for post-tonsillectomy pain – resulting in
a decrease in overall opioid prescribing.
Opioid Prescribing Based on Insurance Status
Following analyses of the health insurance subgroup, it was found that one of the four
hypotheses was supported. Each hypothesis and its application to the literature will be discussed,
below.
H1: In publicly and privately insured post-tonsillectomy and/or adenoidectomy children at
OHSU, rates of codeine prescribing (level and/or trend) decreased following the 2013 FDA
warning on codeine.
Rates of codeine prescribing decreased in both publicly and privately insured children after the
FDA warning and therefore this hypothesis was supported. This present study observed a
significant slope change in codeine prescribing in both groups, indicating a gradual decline in
codeine prescribing in the post-FDA warning period. Prior studies showed a reduction in codeine
prescribing after the FDA warning, yet evaluated prescribing in privately insured children only
(Chua et al., 2017; Van Cleve, 2017). This study adds to the body of knowledge by
demonstrating a reduction in codeine in both publicly and privately insured children.
H2: There is a difference in codeine prescribing (level and/or trend) between publicly and
privately insured post-tonsillectomy and/or adenoidectomy children at OHSU.
Codeine prescribing did not differ between publicly and privately insured children and therefore
this hypothesis was not supported. Literature pertaining to opioid prescribing practices in
publicly versus privately insured children is scant and mixed. Some studies found children with
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public insurance were more likely to receive an opioid (Donohue et al., 2019) while other studies
found publicly insured children were less likely to receive an opioid (Tomaszewski et al., 2018).
In this study, it was hypothesized that prescribing disparities may exist due to provider biases
and/or clinical explanations. However, this study found equitable prescribing between public and
privately insured children. These findings are encouraging, but add little clarity to the mixed
evidence base.
H3: In publicly and privately insured post-tonsillectomy and/or adenoidectomy children at
OHSU, rates of other opioid prescribing (level and/or trend) increased following the 2013 FDA
warning on codeine.
Rates of other opioid prescribing decreased in both publicly and privately insured children and
thus this hypothesis was not supported. Based on prior studies, it was hypothesized the FDA
warning would result in an increase in other opioid prescribing as a result of substituting an
alternative opioid for codeine (Chua et al., 2017; Van Cleve, 2017). However, a reduction in
other opioid prescribing in privately and publicly insured children was found. In this current
study, the FDA warning appeared to decrease prescribing of not only codeine, but also noncodeine opioids. As discussed above, providers may have reduced other opioid prescribing in
favor of non-opioid post-tonsillectomy analgesics.
H4: There is a difference in alternative opioid prescribing (level and/or trend) between publicly
and privately insured post-tonsillectomy and/or adenoidectomy children at OHSU.
Other opioid prescribing did not differ significantly between publicly and privately insured
children and therefore this hypothesis was not supported. Both groups demonstrated a reduction
in other opioid prescribing in the post-FDA warning period, however the timing of the treatment
effect differed. Publicly insured children saw an immediate and abrupt reduction in other opioid
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prescribing compared to a more gradual reduction in privately insured children. This may be
related to a higher baseline level of other opioid prescribing in publicly insured children (99.5%)
when compared with privately insured children (97.6%). Also, publicly insured children in this
study had a greater frequency of OSA (59.6% versus 40.4%) and a greater occurrence of a nonnormal body habitus (63.1% versus 39.6%) than did privately insured children – which may have
prompted an abrupt treatment response in publicly insured children.
Incidental Findings: Opioid Prescribing Based on Age, Procedure Indication and Body
Habitus
Additional findings in various subgroups were of interest. The youngest children in the
sample (0-4.9 years) had the highest starting level of codeine prescribing in the pre-FDA
warning period (2.4%). Codeine, considered a relatively weak opioid, was initially thought to be
safer than other stronger opioids. Prior to the FDA warning, the perceived safety profile of
codeine may have given providers confidence to prescribe the drug to the youngest children.
Codeine prescribing in children age 0-4.9 years decreased following the FDA warning, but
prescribing did not change in children age 5-9.9 or 10-18 years. This is likely due to very low
pre-intervention codeine prescribing rates in the latter age groups (0.41% and nearly 0%,
respectively). Additionally, the youngest children saw a significant and immediate reduction in
other opioid prescribing after the FDA warning whereas older children demonstrated a gradual or
no reduction in other opioid prescribing. Two plausible explanations exist. First, younger
children are higher risk for post-tonsillectomy respiratory compromise (Cote et al., 2015). Also,
many of the post-tonsillectomy codeine-related deaths occurred in young children (2-10 years).
These factors may have prompted providers to be more cautious in prescribing opioids to
younger children. Next, it is documented that older children and adults report higher posttonsillectomy pain than younger children (Alm, Stalfors, Nerfeldt & Ericsson, 2017; Eriksson,
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Nilsson, Bramhagen, Idvall & Ericsson, 2017), possibly explaining why other opioid prescribing
was not reduced in children age 10-18 years.
Opioid prescribing based on procedure indication (OSA versus no-OSA) showed codeine
prescribing fell gradually in both groups. Other opioid prescribing also fell in both groups, but
the timing of the treatment effect differed. In children with OSA, an immediate reduction in
other opioid prescribing occurred. This may be reflective of the heightened risk of perioperative
adverse respiratory events in children with OSA. Canto et al. (2015) reported children with OSA
have a 5-fold increase in the odds for perioperative respiratory events when compared to children
without OSA. Also, studies reported unexpected post-tonsillectomy and/or adenoidectomy
deaths and/or near deaths in children with suspected or confirmed sleep apnea (Coté et al., 2014;
Goldman et al., 2013). Children without OSA also demonstrated a reduction in other opioid
prescribing, though at a more gradual pace. Interestingly, the post-intervention slope of other
opioid prescribing in children without OSA trended downward, but remained relatively flat in
children with OSA. It is plausible that children without OSA underwent adenoidectomy only,
which tends to be less painful and requires fewer opioid analgesics. Conversely, children with
OSA likely underwent combined tonsillectomy and adenoidectomy, which is a more painful
procedure – possibly explaining the relatively flat postintervention trend seen in this group.
Next, children with normal and non-normal body habitus experienced a decline in
codeine and other opioid prescribing. Again, the timing of the treatment effect of other opioid
prescribing differed. Children with non-normal body habitus showed an immediate reduction in
other opioid prescribing whereas children with a normal body habitus demonstrated a more
gradual decline. These findings may be explained given non-normal body habitus, particularly
obesity, increases the risk for perioperative adverse respiratory events in children undergoing
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tonsillectomy and/or adenoidectomy (Goldman et al., 2013; Mortensen et al., 2011). However,
because of the distribution of the sample in this study, the non-normal body habitus category
contained children who were underweight, overweight or obese. Therefore, it cannot be assumed
that all children in the non-normal category were obese. Still, these findings illustrate that body
habitus impacted the timing in which other opioid prescribing fell.
Contribution to the Literature
This study clarified the local impact of the FDA warning on codeine prescribing and
added additional knowledge on codeine/other opioid prescribing in an understudied population.
Prior studies evaluated pre-and post-FDA warning opioid prescribing in privately insured
children only. This study expanded the knowledge base by including publicly insured children in
the sample – and by comparing prescribing in publicly versus privately insured children. This
study also illustrated opioid prescribing trends from 2010 – 2018 and provided information on
the most commonly prescribed post-tonsillectomy opioids at OHSU. Additionally, this study
evaluated opioids prescribed rather than opioids dispensed, which better assesses actual
prescribing practices. Findings from this study are relevant both theoretically and practically, as
discussed below.
Study Implications
Theoretical Implications
Quality of care was a central matter in this study. Using the Institute of Medicine’s
conceptualizations of quality, this study defined quality in terms of safety (halting codeine
prescribing) and equity of care (in all children, regardless of health insurance status). The
Donabedian model served as a framework for how quality was measured in this study. Using the
constructs of structure, process and outcome a linkage was made between the FDA warning
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(structure), prescribing practices (processes) and number of opioid prescriptions (outcomes).
Results of this study support the linkage where prescribing practices and the number of opioid
prescriptions changed as a result of the FDA warning. This was evidenced by an immediate or
gradual reduction in codeine and other opioid prescribing in the post-FDA warning period (main
and subgroup analyses). However, differences in prescribing between publicly and privately
insured children were not apparent – therefore health insurance status did not appear to be an
antecedent factor that influenced outcomes. Still, Donabedian’s model served as a useful
framework to evaluate the influence of structural and process-related factors on outcomes.
Practical Implications
Results have practical implications for providers who prescribe opioids and care for
children undergoing tonsillectomy and/or adenoidectomy. The FDA warning reduced both
codeine and other opioid prescribing at OHSU. Rather than substituting other opioids for
codeine, it appears the FDA warning prompted providers to prescribe less opioids, in general.
This shift in prescribing is encouraging and aligns with recent recommendations to reduce opioid
prescribing in pediatric tonsillectomy and/or adenoidectomy patients (Mitchell et al., 2019).
Additionally, this current study revealed that oxycodone is now the most frequently prescribed
opioid in pediatric tonsillectomy and/or adenoidectomy patients at the study site. This is an
important finding as the knowledge base regarding the impact of pharmacogenetics on
oxycodone metabolism in children develops. Though the CYP34A enzyme is the primary
metabolic pathway of oxycodone, the enzyme CYP2D6 plays a partial role. Children with
atypical CYP2D6 phenotypes (extensive metabolizers) appear to have higher exposure to
oxycodone’s active metabolite, oxymorphone (Balyan et al., 2017). Oxycodone-related toxicity
has not been reported in post-tonsillectomy children – however, providers should consider the
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risks (clinical and genetic) of prescribing the drug. Also, results of this study offer an opportunity
to reinforce the dangers of codeine prescribing in children undergoing tonsillectomy and/or
adenoidectomy. Codeine prescribing in the latter study years was very low – however, there is
evidence of some residual codeine prescribing (0.4% in 2018). This study serves as a useful
reminder that codeine should be avoided in this population. Finally, this study illustrates that
clinical risk factors appear to influence prescribing practices, at least to some extent. It should
continue to be emphasized that young children, children with OSA or obese children are at
greater risk for opioid-related adverse events.
Limitations
This study has limitations. Although the ITS design is regarded as a strong quasiexperimental research design, this study is observational and does not account for all factors that
may influence opioid prescribing. Inherent to the ITS design, threats due to between or withingroup differences are minimized (Bernal et al., 2018; Kontopantelis et al., 2015). Still,
demographic variables were collected and stratified analyses were conducted on groups that
exhibited differences in the pre-and post-FDA warning periods. Next, an ITS design relies on
equally spaced observation intervals and clear differentiation of the pre-and post-intervention
periods. Because of inadequate sample size for monthly observation intervals, data were grouped
into 4-month observation intervals. Fewer observation intervals may have resulted in loss of
statistical power, however adequate observations at each observation interval likely offsets this.
Finally, the pre-intervention trend of the variable codeine exhibited a somewhat irregular pattern.
Violation of the assumption of linearity does not invalidate the analysis, but does weaken it.
Attempts were made to transform the variable, but linearity was not markedly improved.
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Retaining the variable in its original form allowed metrics of interpretation to be meaningful and
consistent across groups.
Next, the EHR was used as the data collection tool in this study. The EHR is generally
regarded as an unbiased data collection tool, however its accuracy relies on individual users who
input the data. The BMI variable had considerable missing data due to missing height
information from the EHR. The missing data was imputed from relevant variables (age, gender,
weight) – still, this introduces bias into the variable. Also, the procedure indication variable
(OSA versus no OSA) relies on CPT and/or ICD codes that tend to be more useful for billing
purposes than clinical purposes. It is conceivable that some children who had evidence of a
sleep-related breathing disorder – but did not have a formal sleep study – were not given a
formal CPT and/or ICD diagnosis of OSA. Additionally, the non-OSA group in the postintervention period was small and estimates may be biased on account of small N. Age groups
were uneven with the majority (>80%) of children in the 0-4.9- or 5-9.9-year categories,
potentially introducing bias into the analyses of opioid prescribing in older children (10-18
years). Next, it was surprising that measurement error afflicted the opioid prescribing variable.
As previously discussed, a plausible EHR technological fault led to a biased estimate of opioid
prescribing in time period 25, necessitating data exclusion. However, a sensitivity analysis
showed the data exclusion did not alter the analysis. Finally, the pharmacy informatics team was
unable to extract the dose of opioid prescribed. The binary yes/no variable of opioid prescribing
cannot account for possible opioid dose reductions that may have occurred in the post-FDA
warning period.
The study site was a large, academic medical center and study findings may not
generalize to other institutions or populations. Demographic characteristics of the sample,
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surgical techniques and prescribing practices may differ across facilities. Also, this study
included only children who underwent outpatient tonsillectomy and/or adenoidectomy. All
children were assumed to be candidates for outpatient surgery, without major comorbidities.
However, clinical characteristics were limited only to OSA status and body habitus; therefore, it
cannot be determined if some children possessed additional comorbidities that may have
influenced prescribing practices.
Combined procedures were intended to be excluded, though the data was not filtered for
this exclusion. However, it was estimated by the otolaryngology team that only a small number
of tonsillectomy and/or adenoidectomies were combined with other non-otolaryngology
procedures. Further, data from OHSU’s perioperative patient registry (Multicenter Perioperative
Outcomes Group e-system) showed < 5% of outpatient tonsillectomy and/or adenoidectomies
were combined with other non-otolaryngology procedures. All opioids in the dataset were
prescribed by otolaryngologists – which linked the opioid prescription to the tonsillectomy
and/or adenoidectomy procedure. Still, combined procedures represent a potential confounder
and limitation to the study.
Finally, no evidence of codeine, hydrocodone or oxycodone shortage were found via the
U.S. FDA’s Drug Shortages Database. However, local shortages or supply chain disruptions
cannot be excluded.
Conclusions and Recommendations for Future Research
The 2013 FDA warning on codeine led to significant changes in codeine and other opioid
prescribing in all children; insurance status did not appear to influence prescribing practices.
Findings from this study are encouraging, but evidence regarding the medical treatment of
publicly versus privately insured children remains mixed. Achieving equity in healthcare
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delivery requires a comprehensive research agenda that considers all sociodemographic variables
that may influence care, including health insurance status. Therefore, the influence of health
insurance status on opioid prescribing should be further explored in future, larger-scale studies.
These studies should be conducted in varied settings including perioperative, emergency
department and primary care settings – in both academic and non-academic/community facilities.
Additionally, qualitative or mixed-method studies may be beneficial to better understand
possible implicit and/or explicit biases in prescribing practices and/or perceptions of regulatory
drug warnings. Future studies should also consider variables not measured in this study,
including surgical technique and dose of opioid prescribed. Next, further studies should ascertain
the impact of genetic variation on oxycodone metabolism in children. Finally, studies should
examine whether non-opioid medications have been substituted for opioids. Tonsillectomy
remains a painful procedure. Research should address the adequacy of analgesia as the opioid
prescribing trend shifts downward.
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Appendix A
-

-

-

ICD-9-CM codes:
- 327.23 (OSA (pediatric)(adult))
- 780.57 (unspecified sleep apnea)
ICD-9-PCS codes:
- 28.2 (tonsillectomy without adenoidectomy)
- 28.3 (tonsillectomy with adenoidectomy)
- 28.6 (adenoidectomy without tonsillectomy)
ICD-10-CM codes:
- G47.33 (OSA (pediatric)(adult))
- G47.30 (unspecified sleep apnea)
ICD-10-PCS codes:
- 0CTP0ZZ (resection of tonsils, open approach)
- 0CTPXZZ (resection of tonsils, external approach)
- 0CTQ0ZZ (resection of adenoids, open approach)
- 0CTQXZZ (resection of adenoids, external approach)
- 0C5P0ZZ (destruction of tonsils, open approach)
- 0C5PXZZ (destruction of tonsils, external approach)
- 0C5Q0ZZ (destruction of adenoids, open approach)
- 0C5QXZZ (destruction of adenoids, external approach)
- 0CBP0ZZ (excision of tonsils, open approach)
- 0CBPXZZ (excision of tonsils, external approach)
- 0CBQ0ZZ (excision of adenoids, open approach)
- 0CBQXZZ (excision of adenoids, external approach)
CPT codes:
- 42820, 42821, 42825, 42826, 42830, 42831, 42835, 42836 (Excision and
Destruction Procedures on the Pharynx, Adenoids, and Tonsils)
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Appendix B
Time Period
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26

Months
2-5 (Feb 2010 – May 2010)
6-9 (June 2010 – Sept 2010)
10-13 (Oct 2010 – Jan 2011)
14-17 (Feb 2011 – May 2011)
18-21 (June 2011 – Sept 2011)
22-25 (Oct 2011 – Jan 2012)
26-29 (Feb 2012 – May 2012)
30-33 (June 2012 – Sept 2012)
34-37 (Oct 2012 – Jan 2013)
40-43 (Apr 2013 – July 2013)
44-47 (Aug 2013– Nov 2013)
48-51 (Dec 2013 – Mar 2014)
52-55 (Apr 2014 – July 2014)
56-59 (Aug 2014 – Nov 2014)
60-63 (Dec 2014 – Mar 2015)
64-67 (Apr 2015 – July 2015)
68-71 (Aug 2015 – Nov 2015)
72-75 (Dec 2015 – Mar 2016)
76-79 (Apr 2016 – July 2016)
80-83 (Aug 2016 – Nov 2016)
84-87 (Dec 2016 – Mar 2017)
88-91 (Apr 2017 – July 2017)
92-95 (Aug 2017 – Nov 2017)
99-99 (Dec 2017 – Mar 2018)
100-103 (Apr 2018 – July 2018)
104-107 (Aug 2018 – Nov 2018)
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Intervention Period
Pre
Pre
Pre
Pre
Pre
Pre
Pre
Pre
Pre
Post
Post
Post
Post
Post
Post
Post
Post
Post
Post
Post
Post
Post
Post
Post
Post
Post

Appendix C
Public
AETNA DIRECT
AETNA NETWORK AETNA NETWORK
AETNA OHSU 250
AETNA OHSU 60/50
AETNA OHSU PPO
ALLEGIANCE
APWU
ATRIO EXCHANGE
BAY AREA HOSPITAL
BC MEDADVANTAGE
BCBS ILLINOIS
BCBS MASSACHUSETTS
BCBS MINNESOTA
BCBS OUT OF STATE
BEECH ST
BLUE CROSS CALIFORNIA
BLUE CROSS FEDERAL
BRIDGESPAN EXCHANGE
*CHAMPVA
CIGNA
CIGNA NETWORK
COMMERCIAL GROUP
CORESOURCE AETNA
COVENTRY FIRST HEALTH
FIRST CHOICE HEALTH
GEHA
GREAT WEST NETWORK
GWH CIGNA
HEALTH FUTURE MANAGED CARE
HEALTHNET HMO/POS/EPO/CC
HEALTHNET MEDICARE PPO
HEALTHNET PPO
HMA/RGA
KAISER ADDED CHOICE
KAISER PEDIATRIC
LIFE TRAC TRANSPLANT
LIFEWISE
LIFEWISE IN NETWORK FIRST CHOICE
LOOMIS COMPANY BENEFITS
MERITAIN HEALTH
MODA AFFINITY
MODA BEACON
MODA CONNEXUS
MODA HEALTH ODS OHSU 250
MODA HEALTH OHP ODS PLUS
MODA MEDICARE PPO
MODA OEBB CONNEXUS

Private
AGENCIES FEDERAL
AMERIGROUP APPLE HEALTH
CAREOREGON MEDICARE ADV
CAWEM INPT
CAWEM NON COV
CCO ADVANCED HEALTH
CCO ALLCARE HEALTH PLAN
CCO CAREOR HEALTH SHARE
CCO CASCADE HLTH ALLIANCE
CCO COLUMBIA PACIFIC
CCO EASTERN OR
CCO FAMILYCARE INC
CCO INTERCOMMUNITY HTLH
CCO JACKSON CARE CONNECT
CCO KAISER HEALTH SHARE
CCO PACIFICSOURCE
CCO PRIMARYHLTH JSPHN CTY
CCO PROVIDENCE HLTH SHARE
CCO TRILLIUM COMMUNITY
CCO TUALITY HEALTH SHARE
CCO UMPQUA HEALTH ALLIANCE
CCO WILLAMETTE VALLEY COM HLTH
CCO YAMHILL COMMUNITY
CHPW APPLE HEALTH
CHPW APPLE HEALTH
CHPW CUP APPLE HEALTH
COORD CARE APPLE HEALTH
MEDICARE A & B
CUP APPLE HEALTH
IDAHO MEDICAID
INDIAN HEALTH SERVICE
MOLINA APPLE HEALTH
MOLINA KAISER APPLE HEALTH
OHP CAREOREGON PLUS
OHP CAREOREGON STANDARD
OHP CASCADE PLUS
OHP DOCS PLUS
OHP DOUGLAS PLUS
OHP DOUGLAS STANDARD
OHP FAMILY CARE PCO PLUS
OHP FAMILY CARE PLUS
OHP INTERCOMMUNITY PLUS
OHP LANE PLUS
OHP MARION POLK PLUS
OHP MIDROGUE PLUS
OHP PACIFICSOURCE PLUS
OHP PACIFICSOURCE STANDARD
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MODA OHSU PPO
MODA PEBB
MODA SUMMIT
MODA SUMMIT PEBB
MODA SYNERGY SUMMIT
MULTIPLAN
MULTIPLAN WRAP
NALC
PACIFICSOURCE
PACIFICSOURCE HEALTHY KIDS
ESSENTIALS/EXPLORER
PHP OPEN IPCO
PHP PEBB STATEWIDE
PHP PERSONAL IPCO
PREMERA OF WA ALASKA
PRIVATE HEALTH CARE SYSTEMS
PROV PREF DIRECT
PROVIDENCE CHOICE PEBB
PROVIDENCE EXCHANGE
PROVIDENCE HEALTH
PROVIDENCE HEALTH PERSONAL OPTION
PROVIDENCE PREF
REGENCE ACCESS
REGENCE BC MEDADVANTAGE PPO
REGENCE BCBS
REGENCE BCBS OHSU PLUS
REGENCE BCBS PAR
SAMARITAN HEALTH
SHRINERS
*TRICARE
*TRICARE WEST HEALTHNET
TUALITY HEALTHCARE
UMR UHC
UNITED HEALTHCARE
UNITED HEALTHCARE NETWORK
UNITED HLTHCARE
*VA COMMUNITY OUTSOURCE
*VA TRIWEST

OHP PCCM PLUS
OHP PLUS OPEN CARD
OHP PROV HEALTH PLUS
OHP TUALITY HEALTHPLUS
OMAP STANDARD
OREGONS HEALTH CO OP
PACIFICSOURCE MEDICARE
PROJECT ACCESS NOW
SAMARITAN HEALTHY KIDS
SAMARITAN MEDICARE
UHC WEST WA APPLE HEALTH
WA COMM HEALTH
WA MEDICAID CUP
WA MEDICAID FEDERAL
WARM SPRINGS MANAGED CARE

*Health Insurance Coverage provided by the government to military personnel. Employmentconnected, not income based and therefore classified as private.
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